WO2012151574A1 - Methods of developing a prognosis for pancreatic cancer and predicting responsiveness to cancer therapeutics - Google Patents
Methods of developing a prognosis for pancreatic cancer and predicting responsiveness to cancer therapeutics Download PDFInfo
- Publication number
- WO2012151574A1 WO2012151574A1 PCT/US2012/036779 US2012036779W WO2012151574A1 WO 2012151574 A1 WO2012151574 A1 WO 2012151574A1 US 2012036779 W US2012036779 W US 2012036779W WO 2012151574 A1 WO2012151574 A1 WO 2012151574A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- vegf
- less
- expression level
- cancer
- targeting agent
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 118
- 238000004393 prognosis Methods 0.000 title claims abstract description 50
- 230000004043 responsiveness Effects 0.000 title claims abstract description 49
- 206010061902 Pancreatic neoplasm Diseases 0.000 title claims abstract description 22
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 title claims abstract description 22
- 201000002528 pancreatic cancer Diseases 0.000 title claims abstract description 22
- 208000008443 pancreatic carcinoma Diseases 0.000 title claims abstract description 22
- 239000012830 cancer therapeutic Substances 0.000 title description 6
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims abstract description 107
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims abstract description 107
- 230000014509 gene expression Effects 0.000 claims abstract description 98
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 87
- 230000008685 targeting Effects 0.000 claims abstract description 86
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 63
- 239000000090 biomarker Substances 0.000 claims abstract description 57
- 201000011510 cancer Diseases 0.000 claims abstract description 52
- 238000011282 treatment Methods 0.000 claims abstract description 50
- 238000011275 oncology therapy Methods 0.000 claims abstract description 44
- 108010017843 platelet-derived growth factor A Proteins 0.000 claims abstract description 34
- 102100034608 Angiopoietin-2 Human genes 0.000 claims abstract description 29
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 claims abstract description 29
- 108010073919 Vascular Endothelial Growth Factor D Proteins 0.000 claims abstract description 29
- 101710088580 Stromal cell-derived factor 1 Proteins 0.000 claims abstract description 27
- 108090001005 Interleukin-6 Proteins 0.000 claims abstract description 25
- 102000004375 Insulin-like growth factor-binding protein 1 Human genes 0.000 claims abstract description 19
- 108090000957 Insulin-like growth factor-binding protein 1 Proteins 0.000 claims abstract description 19
- 108010048036 Angiopoietin-2 Proteins 0.000 claims abstract description 11
- 102000009519 Vascular Endothelial Growth Factor D Human genes 0.000 claims abstract 6
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims description 83
- 230000004083 survival effect Effects 0.000 claims description 69
- 229960005277 gemcitabine Drugs 0.000 claims description 36
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims description 36
- 230000008901 benefit Effects 0.000 claims description 30
- 101100208237 Bos taurus THBS2 gene Proteins 0.000 claims description 27
- 238000004458 analytical method Methods 0.000 claims description 27
- 108090000623 proteins and genes Proteins 0.000 claims description 25
- 101000613820 Homo sapiens Osteopontin Proteins 0.000 claims description 23
- 102100040557 Osteopontin Human genes 0.000 claims description 23
- 102000004169 proteins and genes Human genes 0.000 claims description 22
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 claims description 20
- 101000924533 Homo sapiens Angiopoietin-2 Proteins 0.000 claims description 18
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 claims description 18
- 102100035846 Pigment epithelium-derived factor Human genes 0.000 claims description 14
- 108090000102 pigment epithelium-derived factor Proteins 0.000 claims description 14
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims description 13
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 claims description 13
- 108090001007 Interleukin-8 Proteins 0.000 claims description 13
- 102100021943 C-C motif chemokine 2 Human genes 0.000 claims description 11
- 101710155857 C-C motif chemokine 2 Proteins 0.000 claims description 11
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 claims description 11
- 102000004889 Interleukin-6 Human genes 0.000 claims description 11
- 238000010837 poor prognosis Methods 0.000 claims description 11
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 10
- -1 FGFb Proteins 0.000 claims description 10
- 210000004369 blood Anatomy 0.000 claims description 10
- 239000008280 blood Substances 0.000 claims description 10
- 210000002381 plasma Anatomy 0.000 claims description 10
- 108010081589 Becaplermin Proteins 0.000 claims description 9
- 108010073923 Vascular Endothelial Growth Factor C Proteins 0.000 claims description 9
- 230000009286 beneficial effect Effects 0.000 claims description 9
- 238000002965 ELISA Methods 0.000 claims description 7
- 102100034221 Growth-regulated alpha protein Human genes 0.000 claims description 7
- 101001069921 Homo sapiens Growth-regulated alpha protein Proteins 0.000 claims description 7
- 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 claims description 7
- 102100039418 Plasminogen activator inhibitor 1 Human genes 0.000 claims description 7
- 101150088952 IGF1 gene Proteins 0.000 claims description 5
- 102000004374 Insulin-like growth factor binding protein 3 Human genes 0.000 claims description 5
- 108090000965 Insulin-like growth factor binding protein 3 Proteins 0.000 claims description 5
- 239000003112 inhibitor Substances 0.000 claims description 5
- 125000003729 nucleotide group Chemical group 0.000 claims description 5
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 claims description 4
- 230000001225 therapeutic effect Effects 0.000 claims description 4
- 208000005017 glioblastoma Diseases 0.000 claims description 3
- 238000002493 microarray Methods 0.000 claims description 3
- 210000002966 serum Anatomy 0.000 claims description 3
- 210000002700 urine Anatomy 0.000 claims description 3
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 238000000636 Northern blotting Methods 0.000 claims description 2
- 210000000481 breast Anatomy 0.000 claims description 2
- 208000006990 cholangiocarcinoma Diseases 0.000 claims description 2
- 230000002496 gastric effect Effects 0.000 claims description 2
- 210000003128 head Anatomy 0.000 claims description 2
- 238000003018 immunoassay Methods 0.000 claims description 2
- 238000010166 immunofluorescence Methods 0.000 claims description 2
- 210000004185 liver Anatomy 0.000 claims description 2
- 210000004072 lung Anatomy 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 210000003739 neck Anatomy 0.000 claims description 2
- 230000000955 neuroendocrine Effects 0.000 claims description 2
- 230000002611 ovarian Effects 0.000 claims description 2
- 210000002307 prostate Anatomy 0.000 claims description 2
- 210000001685 thyroid gland Anatomy 0.000 claims description 2
- 238000001262 western blot Methods 0.000 claims description 2
- 102100026019 Interleukin-6 Human genes 0.000 claims 5
- 102000009520 Vascular Endothelial Growth Factor C Human genes 0.000 claims 3
- 102100034871 C-C motif chemokine 8 Human genes 0.000 claims 1
- 101710155833 C-C motif chemokine 8 Proteins 0.000 claims 1
- 230000006820 DNA synthesis Effects 0.000 claims 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 claims 1
- 102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 claims 1
- 108091006374 cAMP receptor proteins Proteins 0.000 claims 1
- AEUKDPKXTPNBNY-XEYRWQBLSA-N mcp 2 Chemical compound C([C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)C1=CC=CC=C1 AEUKDPKXTPNBNY-XEYRWQBLSA-N 0.000 claims 1
- 229960000397 bevacizumab Drugs 0.000 description 35
- 239000000523 sample Substances 0.000 description 28
- 102100038234 Vascular endothelial growth factor D Human genes 0.000 description 23
- 108010074051 C-Reactive Protein Proteins 0.000 description 21
- 102100032752 C-reactive protein Human genes 0.000 description 21
- 239000000902 placebo Substances 0.000 description 21
- 229940068196 placebo Drugs 0.000 description 21
- 239000012491 analyte Substances 0.000 description 13
- 238000003556 assay Methods 0.000 description 10
- 230000035945 sensitivity Effects 0.000 description 10
- 238000002560 therapeutic procedure Methods 0.000 description 10
- 238000012360 testing method Methods 0.000 description 9
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 8
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 8
- 102000004890 Interleukin-8 Human genes 0.000 description 8
- 238000012937 correction Methods 0.000 description 8
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 7
- 102100035194 Placenta growth factor Human genes 0.000 description 7
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 6
- 108010009583 Transforming Growth Factors Proteins 0.000 description 6
- 102000009618 Transforming Growth Factors Human genes 0.000 description 6
- 102100038232 Vascular endothelial growth factor C Human genes 0.000 description 6
- 230000033115 angiogenesis Effects 0.000 description 6
- 108091033319 polynucleotide Proteins 0.000 description 6
- 102000040430 polynucleotide Human genes 0.000 description 6
- 239000002157 polynucleotide Substances 0.000 description 6
- 230000002596 correlated effect Effects 0.000 description 5
- 230000000875 corresponding effect Effects 0.000 description 5
- 206010061289 metastatic neoplasm Diseases 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 208000006265 Renal cell carcinoma Diseases 0.000 description 4
- 206010064930 age-related macular degeneration Diseases 0.000 description 4
- 150000001413 amino acids Chemical group 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 230000002349 favourable effect Effects 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 239000003102 growth factor Substances 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 208000002780 macular degeneration Diseases 0.000 description 4
- 230000001394 metastastic effect Effects 0.000 description 4
- 150000007523 nucleic acids Chemical group 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 239000013610 patient sample Substances 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 4
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 4
- 238000007473 univariate analysis Methods 0.000 description 4
- 206010052747 Adenocarcinoma pancreas Diseases 0.000 description 3
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 238000012286 ELISA Assay Methods 0.000 description 3
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 3
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 3
- 101000595923 Homo sapiens Placenta growth factor Proteins 0.000 description 3
- 239000002147 L01XE04 - Sunitinib Substances 0.000 description 3
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 3
- 239000003798 L01XE11 - Pazopanib Substances 0.000 description 3
- 108010082093 Placenta Growth Factor Proteins 0.000 description 3
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 3
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 3
- 239000002870 angiogenesis inducing agent Substances 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000002790 cross-validation Methods 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 229960000639 pazopanib Drugs 0.000 description 3
- CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 description 3
- 229960003876 ranibizumab Drugs 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 238000000611 regression analysis Methods 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 229960003787 sorafenib Drugs 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 229960001796 sunitinib Drugs 0.000 description 3
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 3
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 238000011269 treatment regimen Methods 0.000 description 3
- WLCZTRVUXYALDD-IBGZPJMESA-N 7-[[(2s)-2,6-bis(2-methoxyethoxycarbonylamino)hexanoyl]amino]heptoxy-methylphosphinic acid Chemical compound COCCOC(=O)NCCCC[C@H](NC(=O)OCCOC)C(=O)NCCCCCCCOP(C)(O)=O WLCZTRVUXYALDD-IBGZPJMESA-N 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- 101001039702 Escherichia coli (strain K12) Methyl-accepting chemotaxis protein I Proteins 0.000 description 2
- 101000617130 Homo sapiens Stromal cell-derived factor 1 Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 102000008212 P-Selectin Human genes 0.000 description 2
- 108010035766 P-Selectin Proteins 0.000 description 2
- 108091008605 VEGF receptors Proteins 0.000 description 2
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 2
- 102100039037 Vascular endothelial growth factor A Human genes 0.000 description 2
- 229960003005 axitinib Drugs 0.000 description 2
- RITAVMQDGBJQJZ-FMIVXFBMSA-N axitinib Chemical compound CNC(=O)C1=CC=CC=C1SC1=CC=C(C(\C=C\C=2N=CC=CC=2)=NN2)C2=C1 RITAVMQDGBJQJZ-FMIVXFBMSA-N 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000010195 expression analysis Methods 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 102000028416 insulin-like growth factor binding Human genes 0.000 description 2
- 108091022911 insulin-like growth factor binding Proteins 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 230000007310 pathophysiology Effects 0.000 description 2
- 229960003407 pegaptanib Drugs 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 238000003196 serial analysis of gene expression Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000005747 tumor angiogenesis Effects 0.000 description 2
- 101000689231 Aeromonas salmonicida S-layer protein Proteins 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 206010052358 Colorectal cancer metastatic Diseases 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- 239000012623 DNA damaging agent Substances 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 229940122029 DNA synthesis inhibitor Drugs 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001001487 Homo sapiens Phosphatidylinositol-glycan biosynthesis class F protein Proteins 0.000 description 1
- 101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 description 1
- 101000955962 Homo sapiens Vacuolar protein sorting-associated protein 51 homolog Proteins 0.000 description 1
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 description 1
- 101000851030 Homo sapiens Vascular endothelial growth factor receptor 3 Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 101000668058 Infectious salmon anemia virus (isolate Atlantic salmon/Norway/810/9/99) RNA-directed RNA polymerase catalytic subunit Proteins 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 244000178870 Lavandula angustifolia Species 0.000 description 1
- 235000010663 Lavandula angustifolia Nutrition 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 101150072055 PAL1 gene Proteins 0.000 description 1
- 101150062285 PGF gene Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 102000001938 Plasminogen Activators Human genes 0.000 description 1
- 108010001014 Plasminogen Activators Proteins 0.000 description 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 108091008103 RNA aptamers Proteins 0.000 description 1
- 238000003646 Spearman's rank correlation coefficient Methods 0.000 description 1
- 101000748795 Thermus thermophilus (strain ATCC 27634 / DSM 579 / HB8) Cytochrome c oxidase polypeptide I+III Proteins 0.000 description 1
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 1
- 102100033179 Vascular endothelial growth factor receptor 3 Human genes 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 238000011226 adjuvant chemotherapy Methods 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000011237 bivariate analysis Methods 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 230000005773 cancer-related death Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000002975 chemoattractant Substances 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 238000011498 curative surgery Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000556 factor analysis Methods 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 description 1
- 238000011223 gene expression profiling Methods 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000012308 immunohistochemistry method Methods 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000001102 lavandula vera Substances 0.000 description 1
- 235000018219 lavender Nutrition 0.000 description 1
- 238000001325 log-rank test Methods 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 238000000491 multivariate analysis Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 229940127126 plasminogen activator Drugs 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000006884 regulation of angiogenesis Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 238000011896 sensitive detection Methods 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 238000012289 standard assay Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 201000005665 thrombophilia Diseases 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 231100000402 unacceptable toxicity Toxicity 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 229940124676 vascular endothelial growth factor receptor Drugs 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G01N2333/485—Epidermal growth factor [EGF] (urogastrone)
Definitions
- pancreatic cancer is one of the leading causes of cancer related death worldwide. Despite modest benefits associated with currently available treatments, the median survival for patients with metastatic pancreatic adenocarcinoma remains under 1 year (6-9 months). The clinical hallmarks of pancreatic cancer include marked desmoplasia, early metastases,, cachexia, and hypercoagulability. The pathophysiology underlying these conditions has been associated with multiple factors associated with tumor angiogenesis and inflammation.
- VEGF targeting agent a VEGF targeting agent
- methods of developing a prognosis for a subject diagnosed with pancreatic cancer methods of developing treatment plans for subjects with cancer.
- methods of predicting responsiveness of a cancer in a subject to a cancer therapy include determining the expression level of at least one biomarker selected from Ang-2, SDF-1 and VEGF-D in a sample from the subject. The levels of the biomarkers are then compared to a reference level of the biomarker and the comparison is used to predict the responsiveness of the cancer to treatment with the cancer therapy including a VEGF targeting agent. In one embodiment, if the levels of VEGF-D are determined to be low (i.e. less than 1050 pg/mL), then treatment with a cancer therapy including a VEGF targeting agent is predicted to be beneficial.
- VEGF-D if the levels of VEGF-D are determined to be in the mid- to high range (i.e. more than 1 100 pg/mL), then treatment with a cancer therapy including a VEGF targeting agent is not predicted to be beneficial.
- the levels of ANG-2 and SDF- ⁇ are low (i.e. 305 pg/mL and 1 100 pg mL, respectively), then treatment with a cancer therapy including a VEGF targeting agent is not predicted to be beneficial
- the levels of SDF-l are high (i .e. more than 1 100 pg/mL) and the levels of OPN are low (i.e. less than 75 ng mL), the treatment with a cancer therapy including a VEGF targeting agent is predicted to be beneficial.
- methods of developing treatment plans for subjects with cancer are provided.
- the prediction of the responsiveness of the cancer to treatment with a cancer therapy including a VEGF targeting agent is used to select a cancer therapy including a VEGF targeting agent if the cancer is predicted to respond to an an ti- VEGF therapy.
- a prediction suggesting that a VEGF targeting agent will not be effective or will be counter-productive will result in development of a treatment plan excluding a VEGF targeting agent
- methods of developing a prognosis for a subject diagnosed with pancreatic cancer include determining an expression level of IGFBP-1 , PDGF-AA and at least one of IL-6 and CRP in a sample from the subject. The levels of the biomarkers are then compared to reference levels. Finally the comparison is used to determine a survival prognosis for the subject. I one embodiment, if the levels of IGFBP-l, PDGF-AA and IL-6 are low (i.e. less than 13,500 pg mL, 250 pg/mL and 20 pg/mL, respectively), then the survival prognosis is more than 6 months.
- the survival prognosis is more than 6 months.
- the levels of IGFBP- L PDGF- AA and CRP are low (i.e. less than 13,500 pg/ niL, 250 pg/mL and 21,000 ng/mL, respectively)
- the survival prognosis is more than 6 months.
- the levels of PALI total and PEDF are also determined to be low (i.e. less than 28,000 pg/mL and 3,600 ng/mL, respectively) then the survival prognosis is more than 6 months.
- Figure 1 is a Spearman-based dendrogram showing the relatecmess of the biomarkers analyzed in the Examples.
- Figure 2 is a set of Kaplan-Meier plots showing the survival data for the gemcitabine + placebo model ( Figure 2 A) and the gemcitabine ⁇ bevacizumab model (Figure 2B). The high risk groups from the multivariate analysis for each is shown in solid lines and the low risk group is shown in dashed lines.
- Figure 3 is a graph showing the hazard ratio plot for each of the biomarkers identified in the univariate analysis as predictive of responsiveness or lack thereof when treated with bevacizumab.
- Figure 4 is a Kaplan-Meier plot showing the survival data of subjects in the gemcitabine + bevaeizumab group (solid line) distinguished by high SDF-1 and low OPN as compared to the gemcitabine + placebo group (dashed line).
- Figure 5 is a Kaplan-Meier plot showing the survival data of subjects is improved in the gemcitabine + placebo group (dashed lines) with low SDF-1 and low ANG-2 as compared to the gemcitabine + bevacizumab group (solid lines).
- Articles "a” and “an” are used herein to refer to one or to more than one (i.e. at least one) of the grammatical object of the article.
- an element 5 ' means at least one element and can include more than one element.
- Methods of predicting responsiveness of a cancer in a subject to a cancer therapy including a VEGF targeting agent, methods of developing a prognosis for a subject diagnosed with pancreaiic cancer, and methods of developing treatment plans for subjects with cancer are provided herein.
- the methods ah rely on detecting or determining the expression level of at least one biomarker or combinations of biomarkers in a sample from a subject diagnosed with cancer.
- the cancer is a solid tumor.
- the present methods permit the personalization of therapy amongst cancer patients, wherein a subject's biomarker profile is predict ve of, or indicative of, treatment efficacy and or survival.
- the methods disclosed herein can be used in combination with assessment of conventional clinical, factors, such as tumor size, tumor grade, lymph node status, family history, and analysis of expression level of additional biomarkers. In this manner, the methods of the present disclosure permit a. more accurate evaluation of prognosis and cancer therapy effectiveness.
- the method includes determining the expression levels of the proteins or the RNA transcripts for the biomarkers provided herein in Tables 5-13 in a sample from a patient with cancer.
- Biomarker expression in some instances may be normalized against the expression levels of all proteins or RNA transcripts in the sample, or against a reference set of proteins or RNA transcripts in the sample.
- the level of expression of the biomarkers is indicative of the prognosis for the subject or predictive of the effectiveness of a particular treatment.
- the methods of the present disclosure can also be used to assist in selecting appropriate courses of treatment and to identify patients that would benefit; from a particular course of therapy.
- the expression of the particular biomarkers described herein provides insight into which cancer treatment regimens will be most effective for the patient. This information can be used, to generate treatment plans for the patient to prolong survival and minimize side effects or cancer therapy related toxicity.
- prognostic performance of the biomarkers and/or other clinical parameters was assessed utilizing a Cox Proportional Hazards Model Analysis, which is a regression method for survival data that provides an estimate of the hazard ratio and its confi dence interval
- the Cox mode! is a well-recognized statistical technique for exploring the relationship between the survival of a patient and particular variables. This statistical method permits estimation of the hazard (i.e., risk) of
- non-human animals of the disclosure includes all vertebrates, e.g., mammals and non -mammals, such as nonhuman primates, sheep, dog, cat, horse, cow, chickens, amphibians, reptiles, and the like.
- the subject is a human patient. More preferably, the subject is a human patient diagnosed with cancer or undergoing, or about to undergo, a cancer treatment regimen.
- the biomarkers of the present disclosure include proteins and genes encoding the proteins.
- the biomarkers analyzed are provided in Table 1 along with an indication of the commonly used abbreviations for each marker.
- Such biomarkers include DNA comprising the entire or partial sequence of the nucleic acid sequence encoding the biomarker, or the complement of such a sequence.
- the biomarker nucleic acids also include RNA comprising the entire or partial sequence of the nucleic acid sequences encoding the proteins of interest,
- a biomarker protein comprises the entire or partial amino acid sequence of any of the biomarker proteins or polypeptides.
- a G-2 angiopoieim-2
- bFGF basic fibroblast growth factor
- HGF hepatocyte growth factor
- IGFBP insulin-like growth factor-binding protein
- PDGF platelet-derived growth factor: PEDF, pigment epithelium-derived factor
- P1GF placental growth factor
- VEGF vascular endothelial growth factor
- sVEGFR soluble vascular endothelial growth factor receptor
- TGFp transforming growth factor beta
- TSP thromhospondin
- CRP c-reactive protein
- PAI-i plasminogen activator inhibitor-!
- fragments and variants of biomarker genes and proteins are also encompassed by the present invention.
- fragment is intended a portion of the polynucleotide or a portion of the amino acid sequence and hence protein encoded thereby.
- Polynucleotides that are fragments of a biomarker nucleotide sequence generally comprise at least 10, 15, 20, 50, 75, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 800, 900, 1 ,000, 1,200, or 1 ,500 contiguous nucleotides, or up to the number of nucleotides present in a full-length biomarker polynucleotide disclosed herein.
- a fragment of a biomarker polynucleotide will generally encode at least 15, 25, 30, 50, 100, 150, 200, or 250 contiguous amino acids, or up to the total number of amino acids present in a full-length biomarker protein of the invention.
- "Variant” is intended to mean substantially similar sequences. Generally, variants of a particular biomarker of the invention will have at least about 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to that biomarker as determined by sequence alignment programs.
- a “biomarker” is a gene or protein whose level of expression in a sample is altered compared to that of a normal or healthy sample or is indicative of a condition.
- the biomarkers disclosed herein are genes and proteins whose expression level correlates with cancer, particularly pancreatic cancer, prognosis or responsiveness of the cancer to a cancer therapy including a VEGF targeting agent.
- the methods for predicting or prognosticating a cancer therapy in a subject includes collecting a patient body sample.
- the sample may or may not include cells.
- the methods described herein may be performed without requiring a tissue sample or biopsy and need not contain any cancer cells.
- sample is intended to include an sampling of cells, tissues, or bodily fluids In which expression of a biomarker can be detected.
- samples include, but are not limited to, biopsies, smears, blood, lymph, urine, saliva, or any other bodily secretio or derivative thereof.
- Blood can include whole blood, plasma (citrate, EDTA, heparin), serum, or any derivative of blood. Samples may be obtained from a patien t by a variety of techniques available to those skilled in the art. Methods for collecting various samples are well known in the art.
- detecting or determining expression is intended determining the quantity or presence of a protein or its RNA transcript for at least one of the biomarkers of Table 1.
- detecting expression encompasses instances where a biomarker is determined not to be expressed, not to be detectably expressed,, expressed at a low level, expressed at a normal level, or overexpressed.
- Methods suitable for detecting or determining the expression levels of biomarkers include, but are not limited to, EL!SA, immunofluorescence, f ACS analysis, Western blot, magnetic Immunoassays, and both antibody-based micro arrays and non-antibody-based microarrays.
- EL!SA immunofluorescence
- f ACS analysis Western blot
- magnetic Immunoassays and both antibody-based micro arrays and non-antibody-based microarrays.
- the gold standard for detection of growth factors and cytokines in blood was the use of E LIS As; however, multiplex technology offers an attractive alternative approach for cytokine and growth factor analysis.
- the advantages of multiplex technology compared to traditional ELISA assays are conservation of patient sample, increased sensitivity, and significant savings in cost, time and labor.
- Luminex bead-based systems are the most established, being used to detect circulating cytokines and growth factors in both mice and humans. This method is based on the use of microparlicles that have been pre- coated with specific antibodies. These particles are then mixed with sample and the captured analytes are detected using specific secondary antibodies. This allows for up to 100 different analytes to be measured simultaneously in a single microplate well.
- the advantages of this flow cytometry-based method compared to traditional ELISA assays are in the conservation of patient samples as well as significant savings in terms of cost and labor.
- An alternative, plate-based system is produced by Meso Scale Discovery (MSD).
- This system utilizes its proprietary Multi-Array® and Multi-Spot® microplates with electrodes directly integrated into the plates. This enables the MSD system to have ultra-sensitive detection limits, high specificity, and low background signal.
- Another plate-based multiplex system i the Searchlight Plus CCD Imaging System produced by Aushon Biosystems. This novel multiplexing technology allows for the measurement of up to 16 different analytes simultaneously in a single microplate well.
- the assay design is similar to a sandwich ELISA where the capture antibodies are pre-spotted into individual wells of a 96-well plate. Samples or standards are added which bind to the specific capture antibodies and are detected using Aushotr s patented SuperSignal ELISA Femto Chemiluminescent Substrate.
- the assay portfolio is well aligned with many of the targets we are interested in measuring and second, the plate-based system has several operational advantages over the flow-based Luminex system, including lower maintenance costs, ease of use, and sim le-to-follow protocols. Notably any suitable assay may be used in the methods described herein.
- Searchlight technology to analyze 7 Phase I/O studies and one large Phase III studies (CALGB 80303). These multiplex analyses have been quality controlled to investigate ⁇ 40 analytes in various patient samples (i.e., serum, citrate plasma, EDTA plasma, and urine).
- Methods for detecting expression of the biomarkers described herein are not limited to protein expression.
- Gene expression profiling including methods based on hybridization analysis of polynucleotides, methods based on sequencing of
- polynucleotides may also be used.
- the most commonly used methods known in the art for the quantification of mRNA expression in a sample include northern blotting and in situ hybridization (Parker and Barnes, Methods ol. Biol. 106:247-83, 1999), RNAse protection assays (Hod, Biotcchniqucs 13:852-54, 1992), PCR-based methods, such as reverse transcription PCR(RT-PCR) (Weis et al., TIG 8:263-64, 1992), and array-based methods (Schena et al, Science 270:467-70, 1995).
- RT-PCR reverse transcription PCR
- antibodies may be employed that can recognize specific duplexes, including DNA duplexes, RNA duplexes, and DNA-RNA hybrid duplexes, or D A-protein duplexes.
- Representative methods for sequencing-based gene expression analysis include Serial Analysis of Gene Expression (SAGE) and gene expression analysis by massively parallel signature sequencing.
- probe refers to any molecule that is capable of selectively binding to a specifically intended target biomolecule, for example, a nucleotide transcript or a protein encoded by or corresponding to a biomarker. Probes can be synthesized by one of skill in the art, or derived from appropriate biological preparations. Probes may be specifically designed to be labeled. Examples of molecules that can be util ized as probes incl ude, but are not limited to, RNA, DNA, proteins, antibodies, and organic molecules.
- predicting responsiveness refers to providing a probability based analysis of how a particular subject will respond to a cancer therapy.
- the prediction of responsi eness is not a guarantee or absolute, only a statistically probable indication of the responsiveness of the subject.
- the prediction of responsiveness to a cancer therapy including a VEGF targeting agent may indicate that the subject is likely to be responsive to a cancer therapy including a VEGF targeting agent or alternatively may indicate that the subject is not likely to be responsive to a cancer therapy including a VEGF targeting agent.
- the prediction may indicate that inclusion of a VEGF targeting agent in a cancer therapy regime may be counter-productive and lead to a worse result for the subject than if no therapy was used or a placebo was used.
- Responsiveness includes but is not limited to, any measure of a likelihood of clinical benefit.
- clinical benefits include an increase in overall survival, an increase in progression free survival, an increase in time to progression, increased tumor response, decreased symptoms, or other quality of li e benefits.
- a VEGF targeting agent includes any therapeutic agent targeting VEGF family members or any member of the VEGF receptor ciass of proteins.
- antibodies specific for VEGF particularly VEGF-A, antibody-conjugated or other bloreagents capable of blocking VEGF mediated signaling, such as VEGF-R binding or competitive inhibitors, small molecules, aptamers, iRNAs, and other non-antibody-based therapeutic reagents.
- Anti-VEGF agents that are currently FDA approved include bevacizumab (AvastinTM), sunitinib (Suten ⁇ TM), sorafenib (NexavarTM), pazopanib ( redesignientTM), ranibizumab (LucentisTM), pegaptanib (MacugenTM) and Axitinib (ln.iyte , M ).
- Bevacizumab is a monoclonal antibody against VEGF that is FDA approved for the treatment of metastatic colorectal cancer, lung cancer, , renal ceil cancer, and
- Sunitinib is a small molecule tyrosine kinase inhibitor that blocks VEGF, PDGF, and cKIT receptors; sunitinib is FDA approved for the treatment of renal cell carcinoma and Gl Stromal tumors (GIST). Sorafenib is a small molecule tyrosine kinase inhibitor that blocks VEGF, PDGF, and cKIT receptors as well as the oncogene Raf; sorafenib is FDA approved for the treatment of renal cell carcinoma and hepatocellular carcinoma.
- Pazopanib (VotrientTM) is a small molecule tyrosine kinase inhibitor thai blocks VEGF, PDGF, and c !T receptors; pazopanib is FDA approved for the treatment of renal cell carcinoma.
- Ranibizumab (LucentisTM) is a Fab fragment antibody that binds VEGF; ranibizumab is FDA approved for the treatment neovascular (wet) age related macular degeneration (AMD).
- Pegaptanib (MacugenTM) is a pegyiaied RNA aptamer that FDA approved- for the treatment neovascular (wet) age related macular degeneration (AMD).
- Axitinib (IniyteTM) is a small molecule tyrosine kinase inhibitor capable of inhibiting VEGFRl, VEGFR2, VEGFR3, PDGFR and.cKIT thai is FDA approved for treatment of renal cell carcinoma. Multiple other VEGF and other angiogenesis inhibitors are in various stages of clinical development.
- the VEGF targeting agents may be used in combination with other cancer therapeutics in a cancer therapy regimen. Combination therapy does not require that multiple cancer therapeutics be administered simultaneously, but only thai the subjects are treated with more than one therapeutic agent during a time span, such as one month, two months or more.
- the VEGF targeting agent may be used in
- gemcitabine was used, but those of skill in the art will appreciate that a wide variety of cancer therapeutic agents are available arid that such agents are often used in combination such that a DNA synthesis inhibitor and other classes of anticancer agents, including but not limited to, other DNA damaging agents, anti-metabolites, hormonal therapies, and signal transduction inhibitors, is combined with a VEGF targeting agent in a cancer therapy.
- the patients were treated with gemcitabine ⁇ placebo or gemcitabine -f bevacizumab.
- the cancer may be selected from any cancer in which a VEGF targeting agent is being considered for therapeutic purposes, in particular, the cancer may be a solid tumor.
- Cancers for which predictions may be made include but are not limited to pancreatic, colorectal, liver, esophageal, gastric, small bowel, cholangiocarcinoma, lung, head and neck, thyroid, melanoma, breast, renal, bladder, ovarian, uterine, prostate, lymphomas, !eukemias, neuroendocrine, glioblastoma or any other form of brain cancer.
- the expression level of at least, one biomarker selected from ANG-2, SDF-l and VEGF-D in a sample from the subject is determined using any one of the detection methods described above. Then the level in the sample from the subject is compared to a reference level of the biomarker.
- the reference level may be determined empirically such as it was in the Examples, by comparison to the levels found in a set of samples from cancer patients treated with cancer therapies including or excluding a VEGF targeting agent with known clinical outcomes for the patients.
- the reference level may be a level of the biomarker found in samples, such as plasma samples, which becomes a standard and can be used as a predictor for new samples.
- the median cut-off levels reported in the Examples may now serve as reference levels for comparison.
- the coefficients of variation were calculated for each biomarker and may be used to set reference levels. For example, a coefficient of variation of 20% would indicate that the median value could be altered by 20% and used as a reference level for the analysis.
- the expression level of ANG-2 and at least one of SDF-i, FGFb, OPN, F1GF and VCAM-1 are determined.
- low levels of ANG-2 in combination with either low levels of SDF-1, FGFb or VCAM-i or high levels of OPN or HGF are predictive of lack of responsl veness of the cancer to treatment including a VEGF targeting agent.
- the prediction indicates unfavorabiiity of including a VEGF targeting agent in the cancer therapy when the expression level of Ang-2 is less than 305 pg/mL (310, 320, 330, 340, 350, 400, 450, or 500 pg/mL) and the expression level of SDF-1 is less than 1100 pg/mL (1200, 1300, 1400, 1500, 1600, 1700, or 2000 pg/mL), FGFb is less than 30 pg/mL (35 .
- VCAM-i is less than 1 ,700 ng/mL (1800, 1900, 2000, 2500, or 3000 ng mL)
- OPN is more than 73 ng/mL (70. 65, 6 ( 3, 55, or 50 ng/mL)
- HGF is more than 800 pg mL (810, 790, 780, 770, 760, or 750 pg mL).
- the expression level of SDF-1 and OPN are determined, in this embodiment, high levels of SDF-1 and low levels of OPN are predictive of responsiveness to a VEGF targeting agent.
- the prediction favors responsiveness of the cancer to a cancer therapy including a VEGF targeting agent when the expression level of SDF-1 is more than 1 100 pg/mL (1050, 1000, 950, 900, 850, or 800 pg/mL) and OPN is less than 75 ng/mL (80, 85, 90, 95, or 100 ng mL).
- Responsiveness to a VEGF targeting agent indicates a significant increase in clinical benefit for subjects treated with a VEGF targeting agent.
- the expression level of SDF-I and at least one of PDGF- AA, 1GFBP-3, VEGF-R l or MCP-1 are determined.
- low levels of SDF-1 in combination with either low levels of MCP-i or high levels of PDGF-AA, 1GFBP-3, or VEGF-RJ are predictive of lack of responsiveness of the cancer to ireatnieni including a VEGF targeting agent, The prediction indicates unfavorability of including a VEGF targeting agent in the cancer therapy when the expression level of SDF-1 is less than 1 100 ng/mL (1200, 1300, 1400, 1500, 1600, 1700, or 2000 pg/mL) and the expression level of MCP-1 is less than 525 pg/mL (550, 575.
- VEGF-AA is more than 230 pg/mL (200, 175, 150, 125, 100, 75, or SO g/mL)
- IGFBP-3 is more than 700,000 ng/iriL (650,000, 600,000, 550,000, 500,000 or 450,000 ng/mL) or VEGF-R1 is more than 120 pg/mL. ( 100, 90, 80, 70 or 60 pg/mL). Lack of responsiveness to a VEGF targeting agent indicates a significant increase in clinical benefit for subjects not treated with a VEGF targeting agent.
- the expression level of HGF and at least one of MCP-1 or IGF-1 are determined, In this embodiment, high levels of HGF in combination with either low levels of MCP-1 or high levels of IGF-1 are predictive of lack of
- the prediction indicates unfavorability of including a VEG F targeting agent in the cancer therapy when the expression level of HGF is more than 800 pg/raL (750, 700, 650, 600 or 550 pg/mL) and the expression level of MCP-1 is less than 525 pg/mL (550, 575, 600, 650, 700, or 750 pg/mL) o IGF-1 is more than 690 pg mL (675, 650, 625, 600, 550, 500 pg/mL). Lack of responsiveness to a VEGF targeting agent indicates a significant increase in clinical benefit for subjects not treated with a VEGF targeting agent.
- the expression level of VEGF-C and GROa are determined.
- low levels of VEGF-C in combination with high levels of GROa are predictive of lack of responsiveness of the cancer to treatment including a VEGF targeting agent.
- the prediction indicates unfavorability of including a VEGF targeting agent in the cancer therapy when the expression level of VEGF-C is less than 575 pg/mL (600, 625, 650, 675, 700 or 725 pg/mL) and the expression level of GROa is more than 70 pg/mL (65, 60, 55, 50, or 45 pg/mL).
- low levels of VEGF-D are predictive of responsiveness to a VEGF targeting agent.
- the prediction favors responsiveness to a cancer therapy including a VEGF tai-geting agent when the expression level of VEGF-D is less than 1050 pg/mL (1075, 1 100, 1 125, 1 150, 1 175, 1200, or 1250 pg/mL). Responsiveness to a VEGF targeting agent indicates a significant increase in clinical benefit for subjects treated with a VEGF targeting agent.
- median, to high levels of VEGF-D are predictive of lack of responsiveness of the cancer to treatment including a VEGF targeting agent.
- the prediction is unfavorable for responsiveness to a cancer therapy including a VEGF targeting agent when the expression level of VEGF-D is more than 1100 pg/mL (1075 , 1050, 1025, 1000, 950, or 900 pg/mL).
- Lack of responsiveness to a VEGF targeting agent indicates a significant increase in clinical benefit for subjects not treated with a VEGF targeting agent.
- the levels of SDF-1, ANG-2 and OPN may all be determined in a sample from the subject. The levels may be compared to the reference levels and a prediction made. The prediction is favorable for responsiveness to a cancer therapy including a VEGF targeting agent if the SDF-1 levels are high, and the OPN levels are low.
- a sample with low SDF-1 and low ANG-2 will be predictive of lack of effectiveness of a VEGF targeting agent
- the test may further include VEGF-D, such that inclusion of a VEGF targeting agent is predictable to be favorable if the VEGF-D and OPN levels are low and the SDF-1 levels are high.
- VEGF-D levels are not low, but instead are in the mid to high range as compared to the reference levels and the sample has low SDF-1 and low ANG-2, then a VEGF targeting agent will be predicted to not be effective as part of the cancer therapy.
- Methods of developing a prognosis, in particular a survival or progression free survival prognosis, for a subject with pancreatic cancer is also provided herein.
- the prognosis is independent of cancer therapeutic or cancer treatment regimen employed.
- the subject may have localized, advanced or metastatic cancer.
- the method includes determining or detecting the expression level of biomarkers including IGFBP-1, PDGF-AA and at least one of IL-6 and CRP in a sample from the subject. The levels of the biomarkers present in the sample are then compared to reference levels as described above. Finally by comparison to the reference levels a prognosis for the subject can be determined.
- the expression levels of IGFBP-1 , PDGF-AA and IL-6 or CRP are measured and low levels are indicative of a better prognosis and high levels are indicative of poor prognosis, in one embodiment, the survival prognosis for the subject is less than 6 months when the expression level of IGFBP-1 is more than 13,000 pg/mL (12,750, 12,500, 12,000, 11,000, 10,000, 9,000 pg/mL), PDGF-AA is more than 225 pg/raL (200, 175, 150, 125, 100 or 75 pg/mL) and either IL-6 is more than 1.5 pg/mL (12, 10, 8, or 6 pg/mL) or CRP is more than 20,000 ng mL (39,000, 18,000, 17,000, 16,000 or 15,000 ng mL).
- the survival prognosis for the subject is more than 6 months when the expression level of IGFBP-I is less than 13,500 pg/mL (13,250, 14,000, 15,000, 16,000, 17,000 pg/mL), PDGF-AA is less than 250 pg/mL (275, 300, 325, 350 or 400 pg/mL) and either IL-6 is less than 20 pg/mL (25, 30, 40, 50, 60, or 70 g mL) or CRP is less than 21 ,000 ng mL (22,000, 23,000, 24,000, 25,000 or 26,000 ng/mL).
- the expression level of IGFBP-i, PDGF-AA and CRP and the expression level of at least one of PAi-1 -total and PEDF are determined and low levels are indicative of a better prognosis and high levels are indicative of a poor prognosis.
- the survival prognosis for the subject is less than 6 months when the expression level of IGFBP-1 is more than 13,000 pg/mL (12,750, 12,500, 12,000, 1 1 ,000, 10,000, 9,000 pg/mL), PDGF-AA is more than 225 pg/mL (200, 175, 150, 125, 100 or 75 pg/mL), CRP is more than 20,000 ng/mL (19,000, 18,000, 17,000, 16,000 or 15,000 ng/mL), PAI-1 total is more than 2?,000pg/mL (26,000, 25,000, 24,000, 23,000 or 22,000 pg mL) and PEDF is more than 3,500 ng/mL (3250, 3000, 2750, 2500, or 2000 ng mL).
- the survival prognosis for the subject is more than 6 months when the expression level of IGFBP-1 is less than 13,500 pg/mL (13,250, 14,000, 15,000, 16,000, 17,000 pg mL), PDGF-AA is less than 250 pg mL (275, 300, 325, 350 or 400 pg/mL ⁇ , CRP is less than 21,000 ng/mL (22,000, 23,000, 24,000, 25,000 or 26,000 ng/mL), PAI-1 total is less than 28,000 pg/mL (29,000, 30,000, 31,000 or 32,000 pg/mL) and PEDF is less than 3,600 ng/mL (3750, 4000, 4250, 4500, or 5000 ng/mL).
- the subject is being treated with emcitabine alone.
- the expression level of IGFBP-1, PDGF-AA and IL-6 and at least one of PDGF-BB and TSP-2 are determined.
- low levels of the biomarkers are indicative of a better prognosis and high levels are indicative of a poor prognosis.
- the survival prognosis for the subject is less than.
- IGFBP- 1 6 months when the expression level of IGFBP- 1 is more than 13,000 pg mL (12,750, 12,500, 12,000, 1 ,000, 10,000, 9,000 pg/mL), PDGF-AA is more than 225 pg/raL (200, 175, 150, 125, 100 or 75 pg mL), IL-6 is more than 15 pg/mL (12, 10, 8, or 6 pg/mL), PDGF-BB is more than 180 pg mL (175, 150, 125, 100, or 75 pg/mL) and TSP-2 is more than 20,000 pg mL (19,000, 18,000, 17,000, 16,000 or 15,000 pg/mL).
- the survival prognosis for the subject is more than. 6 months when the expression level of IGFBP-l is less than 13,500 pg/mL (13.250, 14,000, 15,000, 16,000, 17,000 pg/mL), PDGF-AA is less than 250 pg/mL (275, 300, 325, 350 or 400 pg/mL), IL-6 is less than 20 pg/mL (25, 30, 40, 50, 60, or 70 pg/raL), PDGF-BB is less than 190 pg/mL (200, 225, 250, 300, 350 or 400 pg raL) and TSP-2 is less than 21 ,000 pg mL (22,000, 23,000, 24,000, 25,000 or 26,000 pg/raL).
- the subject is being treated with gemcitabine and a VEGF targeting agent.
- the expression level of at least one of ICAM-1, Ang2, IL- 8, TSP-2, VCAM-1 , ⁇ -1 , and IGF-.! are determined.
- low levels of ICAM-1, Ang2, IL-8, TSP-2, VCAM-1, or PAI-1 -active as compared to the reference level are indicative of a better prognosis and high levels of ICAM-1 , Ang2, IL-8, TSP-2, VCAM-1 , or PAI-1 -active as compared to the reference level are indicative of a poor prognosis
- high levels of IGF-1 as compared to the reference level is indicative of a better prognosis and low levels of IGF-1 as compared to the reference level is indicative of a poor prognosis.
- the survival prognosis for the subject is less than 6 months when the expression level of IGFBP-l is more than 13,000 pg mL (.12,750, 12,500, 12,000, 11 ,000, i 0,000, 9,000 pg/mL), or ICAM- 1 is more than 350 ng/mL (300, 275, 250, 225, or 200 ng/mL), or Ang2 is more than 300 pg/mL (275, 250, 225, 200 5 175 or 150 pg/mL), or CRP is more than 20,000 ng/raL( 19,000, 18,000, 17,000, 16,000 or 15,000 ng/mL), or IL-8 is more than 49 pg/mL (45, 40, 35, 30 or 25 pg/mL), or IL-6 is more than 17 pg/mL(35, 12, 10, 8, or 6 pg/mL), or TSP-2 i more than 20,000 pg/mL (19,000, 18,000,
- survival prognosis for the subject is more than 6 months when the expression level of iGFBP-l is less than 13,500 pg/mL (13,250, 1.4,000, 15,000, i 6,000, 17,000 pg/raL), or ICAM- 1 is less than 360 ng/mL (375, 400, 425, 450, 475, or 500 ng/mL), or Ang2 is less than 305 pg/mL (310, 320, 330, 340, 350, 400, 450, or 500 pg/mL), or CRP is less than 21,000 ng/mL (22,000, 23,000, 24,000, 25,000 or 26,000 ng/mL), or IL--8 is less than 50 pg/raL (55, 60, 65, 70, 75, 80 or 85 pg/raL), or 1L-6 is less than 18 pg/tnL (20, 25, 30, 40, 50, 60, or 70 pg/mL), or TSP-2 i
- Treatment plans may be developed using the predictions of the responsiveness of the cancer to treatment with a cancer therapy including an antibody specific for VEGF-A obtained using the methods described herein to determine whether treatment of the subject with a cancer therapy including a VEGF targeting agent may e beneficial.
- the treatment plan will include a VEGF targeting agent if such a therapeutic is expected to be beneficial and the treatment plan will not include a VEGF targeting agent if it is not predicted to. be clinically beneficial to the subject as described above.
- Gemcitabine (1 ,000mg/m 2 ) was administered intravenously over 30 rainut.es on days 1. 8, and 15 of a 28-day cycle.
- Bevacizumab 10 mg/kg or placebo was given in travenously after gemcitabine on days 1 and 15 of each cycle, Bevacizumab or placebo dose was Initiaiiy given over 90 minutes, and if no infusion reaction occurred, the second dose was given over 60 minutes, and subsequent doses were given over 30 minutes, IYeatment continued until progressive disease, unacceptable toxicities, or withdrawai of consent.
- Peripheral venous blood was collected from consenting patients into lavender (EDTA anticoagulant) vacutakiers for plasma isolation. The tubes were centrifuged at 2500 g for 15 minutes within 30 minutes of collection. Plasma was aliquoted into cryoviais, snap frozen, and samples shipped for centralized storage at the CALGB Pathology Coordinating Office. Before analysis, all patient samples were shipped to our laboratory (Duke/CALGB Molecular Reference Lab), thawed on ice, re-aliquoted based on specific assay requirements and stored at -80°C. Ail assays were performed in triplicate after 2 freeze-thaw cycles only and all analysis was conducted while blinded to clinical outcome.
- Plasma samples were thawed on ice, centrifuged at 20,000 x g for 5 min to remove precipitate and loaded onto Searchlight plates with standard protein controls. Samples and standards were incubated at room temperature for 1 hour with shaking at 950 rpni (Lab-Line Titer Plate Shaker, Model 4625, Bamstead, Dubuque, IA). Plates were washed three times using a .plate washer (Biotek Instruments, inc.. Model ELx405, Winooski, VT), biotinylaied secondary antibody added, and incubated for 30 min. After washes, streptavidin-HRP was added, incubated for 30 min, washed again, and
- IGF- 1 3.73 18 IGFBP-1 14.46
- Patterns of expression were analyzed at baseline and were correlated with overall survival (OS) and progression free survival (PFS) using univariate Cox proportional hazard regression models and multivariate Cox models with leave-one-out cross validation. Spearman's rank correlation coefficients were calculated for all pairs of analytes. Unsupervised hierarchical clustering of analytes was also performed to produce dendrogram plots. Data indicate that several anaiyte clusters reflect known biological categories. This data is summarized in Figure 1 below.
- the primary endpoint of interest will be overall survival (OS) with correlation to the blood analytes; however, progression-free survival (PFS) was evaluated.
- Cox regression analysis was performed to assess the prognostic value of blood analytes for the clinical endpoints of interest. For each analyte, univariate Cox regression analysis was performed to assess the associations with OS and PFS ( ;:: 0,01 ).
- Cox regression models were performed for Gem+Piacebo and Gem-s-Bev separately. Raw, continuous analytes intensities for baseline measures were used. Summary statistics included the hazard ratios and associated confidence intervals. For each analyte, the inclusion of potential confounding factors was explored. These factors included; gender, extent of disease (locally advanced vs metastatic), age (continuous), and performance status (0, 1 , 2).
- prognostic models were built with multivariate Cox regression analysis using the most informative analytes chosen from leave-one-out cross-validation for Gem+Placebo and Gem+Bev separately.
- the training samples were used to build a Cox regression model for predicting the survival of the testing samples.
- the predicted survival times were used to split the groups in half into high and low risk groups. Kaplan-Meier estimates of the hazard profiles for these two groups were produced.
- IL-8(pg/mL) All 328 49.2 0.59 2061.93 lL-8(pg/mL) 169 47.33 0.6 2061.93 iL-8(pgmL) 2 159 52.47 0.59 757.87
- PAIl-act(pgmL) 2 159 2517.73 121.07 31039.47
- PAIl-tot(pgmL) All 328 27861.7 175.77 259313.3 j PAIl-iot(pg/mL) i 169 29570 175.77 259313.3 j PAl]-iot(pg/mL) 2 159 25866.7 5230 189496.7
- PDGF-AA(pg/mL) 2 159 219,93 14.87 3544.67
- PDGFbb(pgniL) 2 159 190.27 5.85 1386.13
- PEDF(pg/roL) 1 169 3562750 2636.55 78551 3
- VCAM-l(pg/mL) 3 169 1621583 880 7199837
- VCAM-l (pg mL) 2 159 1599333 225900 7973367
- VEGF-C(pg mL) 2 159 554.3 44.19 4732.27
- VEGF-D(pgZmL) 1 169 1574.07 70.31 13233.27
- VEGF-D(pg/mL) 2 159 1553.73 359.93 25382.27
- VEGF-Rl(pg mL) 1 169 130.33 8.2 16940.47
- VEGF-R2(pg/mL) All 328 3790.5 34.17 l 3lj83 j
- VEGF ⁇ R2(pg/mL) 1 169 3806.67 34.17 39032.83
- VEGF ⁇ R2(pg mL) 2 159 3731.33 826.33 35116.17
- IGFBP-1 " o.ooooi 4.2 (3.5,5.6) j 2 ⁇ 5 ! (2.0,3.9) 1.4 ! (1.1 ,2.0)
- analytes tha is prognostic univariately for overall survival using the Cox Proportional Hazard model. On the right hand side, it indicates the median survival time and its 95% C.I for iess than median and greater than median level of the anaiytes. All anaiytes presented remain significant (p ⁇ 0.05) after accounting for multiple parameter testing using bonferroni correction methods, *from Cox proportional hazard model using continuous analyte values.
- TSP-2, CRP, IL-6, IGFBP-1 , Ang-2, ICAM-1, VCAM-1, and iGF-1 were significantly correlated with overall survival in the gemcitabine/bevacizumab group (Table 7).
- TSP-2, CRP, IL-6, IGFBP-1, Ang-2, ICAM-1, and VCAM-1 were significantly correlated with progression free survival in the gemcitabine bevacizumab group (Table 8), it should be noted that high consistency was observed across both cohorts. All of these factors were unfavorable prognostic markers, where higher levels were associated with a less favorable outcome. The only notable exception was IGF-1, where higher levels were associated with a .more favorable outcome.
- Tables 9 and 10 are composite lists of anaiytes that are prognostic for overall survival and progression free survival irrespective of treatment condition, respectively.
- Multivariate prognostic models for OS were developed using a leave one out, cross-validation approach.
- two 5-anaIyte models for risk were developed, one for the gemcilabine + placebo cohort, and another for gemcitabine + bevacizumab cohort (see Table 1 1),
- the gemcitabine + placebo model for OS consisted of IGFBP-1, CRP, PDGF-AA, ⁇ -total, and PEDF. This model was associated with a hazard ratio of 2.0, with corresponding mediaii survivals of 3.3 and 7.3 months for the high and low-' risk groups, respectively.
- the gemcitabine ⁇ ⁇ bevacizumab mode
- Predictive markers were identified using the Cox proportional hazards model. Analyte values were evaluated at both median and quartile outpoints. Three markers were identified as being predictive for bevacizumab benefit (or lack of benefit); VEGF- D, SDF1, and Ang-2. See Table 12.
- the model was associated with a hazard ratio of 0.55, with corresponding median survivals of 5.1 and 9.0 months for the gemcitabine -+ ⁇ placebo group (shown in dashed lines) and gemcitabine ⁇ bevacizumab (shown in solid lines), respectively.
- the bivariate model which most strongly predicted for worse survival in the gemcitabine + bevacizumab group was found to be SDF1 ( ⁇ median) and Ang2 ( ⁇ median). See Figure 5.
- This model was associated with a hazard ratio of 2.2, with corresponding median survivals of ,10.4 and 6.7 months for the gemcitabine + placebo group (shown in dashed lines) and gemcitabine + bevacizumab (shown in solid lines).
- This multiplex angiome analysis of CALGB 80303 is one of the largest such analyses reported to date, and the first in metastatic pancreatic cancer, hi this large multicenter study, technical analyses were robust with good sensitivity and low variability, which were generally comparable to single kit ELISAs.
- Unsupervised hierarchical clustering identified potential patterns of analyte expression, with suggested grouping among VEGF/PDGF family members, ⁇ family members, and various inflammatory and coagulation factors.
- Such analyses particularly across cancer types and in the settings of tumor response and progression, may provide novel insights into the co and counter regulation of these factors and their underlying biology.
- prognostic markers were identified. This analysis is the largest and most comprehensive to date. These laboratory based prognostic markers were more powerful than traditional clinical factors and they remained highly statistically significant even after adjustment for known clinical factors. Most of these markers are involved in tumor related angiogenesis, inflammation, and coagulation, confirming the clinical importance of the underlying pathophysiology of pancreatic cancer, indeed, ras mutations, which are present in approximately 90% of pancreatic adenocarcinomas, have been associated with the up-regulation of multiple factors related to inflammation and inflammatory angiogenesis and targeting these factors has been shown to inhibit the growth of xenograft and genetically modified mouse models of pancreatic cancer. Clinical trials with agents that inhibit these pathways are ongoing in various cancers, including pancreatic cancer; however, the value of targeting these factors in patients with pancreatic cancer is not yet known.
- VEGF-D vascular endothelial growth factor
- VEGF-D was identified as a strong candidate for predicting sensitivity and resistance to bevacizumab in this population.
- Other candidates were also identified, highlighting the known complexity of tumor angiogenesis and pancreatic cancer.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- General Engineering & Computer Science (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Methods of predicting responsiveness of a cancer in a subject to a cancer therapy including a VEGF targeting agent are provided herein. The methods include detecting the expression level of at least one biomarker selected from ANG-2, SDF-1 and VEGF-D in a sample from the subject and using the expression levels to determine whether the VEGF targeting agent will be effective to treat the cancer in the subject. The predictions may be used to develop treatment plans for the subjects. Methods of developing a prognosis for a subject with pancreatic cancer are also provided. These methods include determining the expression level of IGFBP-1, PDGF-AA and at least one of IL-6 or CRP in a sample from a subject with pancreatic cancer.
Description
METHODS OF DEVELOPING A PROGNOSIS FOR PANCREATIC CANCER AND PREDICTING RESPONSIVENESS TO CANCER THERAPEUTICS
CROSS-REFERENCE TO RELATED APPLICATIONS This patent application claims the benefit of priority of United States Provisional
Patent Application No.61/482, 757, filed May 5, 201 1 , which is incorporated herein by reference in its entirety.
INTRODUCTION The goal of all targeted therapies and personalized medicine in general is to define which patients are most or least likely to benefit or have toxicity from a given treatment and to provide patients with a more accurate prognosis. Similarly, almost all cancer patients develop resistance to any given therapy; defining the mechanisms of this resistance helps direct the use of other therapies, including combination regimens to delay, prevent, or overcome this resistance,
Clinically, there have been several reports of biomarkers whose expression levels change in response to treatment. Multiple groups have shown that increased levels of various angiogenesis factors, including VEGF, correlate with worse prognosis or outcome in general. Similarly, several groups have described in patients changes in various angiogenesis factors with anti-VEGF treatment, including VEGF, P!GF, SDFl, Ang2, and sVEGFR2, among others. Many of these changes are seen in preclinical models, even in non-tumor bearing mice suggesting these responses are at bast partially host derived. In preclinical models, factors mediating resistance to anti-VEGF therapy have been described. In the clinic, however, markers that predict which patients will derive greater or lesser benefit from anti-VEGF therapy have been elusive. This may relate to many factors, including technical limitations in assay methods and target abundance or stability. The difficulty in identifying such biomarkers may also relate to the context and complexity of co - and counter- regulation of angiogenesis. Lastly, this information can only be reliably derived from large randomized trials.
By way of example, pancreatic cancer is one of the leading causes of cancer related death worldwide. Despite modest benefits associated with currently available treatments, the median survival for patients with metastatic pancreatic adenocarcinoma remains under 1 year (6-9 months). The clinical hallmarks of pancreatic cancer include marked desmoplasia, early metastases,, cachexia, and hypercoagulability. The pathophysiology underlying these conditions has been associated with multiple factors associated with tumor angiogenesis and inflammation. While many angiogenic and inflammatory makers have been profiled in pancreatic cancer, these analyses have typically been limited by the size and quality of the available datasets, and by the technical limitations of standard assay ELISA methods, which significantly limited the number of factors that could be evaluated in a given sample. Having biomarkers or sets of biomarkers that can provide pancreatic cancer patients with a more accurate prognosis and predictions regarding the responsiveness to cancer therapies would be helpful to patients and to society.
SUMMARY
Provided herein are methods of predicting responsiveness of a cancer in a subject to a cancer therapy including a VEGF targeting agent, methods of developing a prognosis for a subject diagnosed with pancreatic cancer, and methods of developing treatment plans for subjects with cancer.
In one aspect, methods of predicting responsiveness of a cancer in a subject to a cancer therapy includmg a VEGF targeting agent are provided. These methods include determining the expression level of at least one biomarker selected from Ang-2, SDF-1 and VEGF-D in a sample from the subject. The levels of the biomarkers are then compared to a reference level of the biomarker and the comparison is used to predict the responsiveness of the cancer to treatment with the cancer therapy including a VEGF targeting agent. In one embodiment, if the levels of VEGF-D are determined to be low (i.e. less than 1050 pg/mL), then treatment with a cancer therapy including a VEGF targeting agent is predicted to be beneficial. In another embodiment, if the levels of VEGF-D are determined to be in the mid- to high range (i.e. more than 1 100 pg/mL), then treatment with a cancer therapy including a VEGF targeting agent is not predicted to
be beneficial. In another embodiment, if the levels of ANG-2 and SDF-ί are low (i.e. 305 pg/mL and 1 100 pg mL, respectively), then treatment with a cancer therapy including a VEGF targeting agent is not predicted to be beneficial In another embodiment, if the levels of SDF-l are high (i .e. more than 1 100 pg/mL) and the levels of OPN are low (i.e. less than 75 ng mL), the treatment with a cancer therapy including a VEGF targeting agent is predicted to be beneficial,
in anothe aspect, methods of developing treatment plans for subjects with cancer are provided. In these methods the prediction of the responsiveness of the cancer to treatment with a cancer therapy including a VEGF targeting agent is used to select a cancer therapy including a VEGF targeting agent if the cancer is predicted to respond to an an ti- VEGF therapy. In an alternative embodiment, a prediction suggesting that a VEGF targeting agent will not be effective or will be counter-productive will result in development of a treatment plan excluding a VEGF targeting agent,
in yet another aspect, methods of developing a prognosis for a subject diagnosed with pancreatic cancer are provided. These methods include determining an expression level of IGFBP-1 , PDGF-AA and at least one of IL-6 and CRP in a sample from the subject. The levels of the biomarkers are then compared to reference levels. Finally the comparison is used to determine a survival prognosis for the subject. I one embodiment, if the levels of IGFBP-l, PDGF-AA and IL-6 are low (i.e. less than 13,500 pg mL, 250 pg/mL and 20 pg/mL, respectively), then the survival prognosis is more than 6 months. In this embodiment, if the levels of PDGF-BB and TSP-2 are also determined to be low (i.e. less than 190 pg/mL and 21,000 pg/mL, respectively) then the survival prognosis is more than 6 months. In another embodiment, if the levels of IGFBP- L PDGF- AA and CRP are low (i.e. less than 13,500 pg/ niL, 250 pg/mL and 21,000 ng/mL, respectively), then the survival prognosis is more than 6 months. In this embodiment, if the levels of PALI total and PEDF are also determined to be low (i.e. less than 28,000 pg/mL and 3,600 ng/mL, respectively) then the survival prognosis is more than 6 months.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 is a Spearman-based dendrogram showing the relatecmess of the biomarkers analyzed in the Examples.
Figure 2 is a set of Kaplan-Meier plots showing the survival data for the gemcitabine + placebo model (Figure 2 A) and the gemcitabine ÷ bevacizumab model (Figure 2B). The high risk groups from the multivariate analysis for each is shown in solid lines and the low risk group is shown in dashed lines.
Figure 3 is a graph showing the hazard ratio plot for each of the biomarkers identified in the univariate analysis as predictive of responsiveness or lack thereof when treated with bevacizumab.
Figure 4 is a Kaplan-Meier plot showing the survival data of subjects in the gemcitabine + bevaeizumab group (solid line) distinguished by high SDF-1 and low OPN as compared to the gemcitabine + placebo group (dashed line).
Figure 5 is a Kaplan-Meier plot showing the survival data of subjects is improved in the gemcitabine + placebo group (dashed lines) with low SDF-1 and low ANG-2 as compared to the gemcitabine + bevacizumab group (solid lines).
DETAILED DESCRIPTION
For the purposes of promoting an understanding of the principles of the present disclosure, reference will now be made to preferred embodiments and specific language will be used to describe the same. It will nevertheless be understood that no limitation of the scope of the disclosure is thereby intended, such alteration and further modifications of the disclosure as il lustrated herein, being contemplated as would normally occur to one skilled in the art to which the disclosure relates.
Articles "a" and "an" are used herein to refer to one or to more than one (i.e. at least one) of the grammatical object of the article. By way of example, "an element5 ' means at least one element and can include more than one element.
Unless otherwise defined, all technical terms used herein have the same meaning as commonl understood by one of ordinary skill in the art, to which this disclosure belongs.
We sought to identify which growth factors, cytokines, or other blood-based markers predict for sensitivity or resistance to a given therapy, particularly a ti-VEGF therapy, in this case, we were particularly interested in determining which factors (or groups of factors ) predict for sensitivity and acquired resistance to bevacizumab, and/or which factors predict for hevacizumab related toxicity. Describing patterns of co~ and counter-regulation among these factors was thought to be critical t understanding this sensitivity and resistance.
Methods of predicting responsiveness of a cancer in a subject to a cancer therapy including a VEGF targeting agent, methods of developing a prognosis for a subject diagnosed with pancreaiic cancer, and methods of developing treatment plans for subjects with cancer are provided herein. The methods ah rely on detecting or determining the expression level of at least one biomarker or combinations of biomarkers in a sample from a subject diagnosed with cancer. Suitably, the cancer is a solid tumor.
Thus, the present methods permit the personalization of therapy amongst cancer patients, wherein a subject's biomarker profile is predict ve of, or indicative of, treatment efficacy and or survival. The methods disclosed herein can be used in combination with assessment of conventional clinical, factors, such as tumor size, tumor grade, lymph node status, family history, and analysis of expression level of additional biomarkers. In this manner, the methods of the present disclosure permit a. more accurate evaluation of prognosis and cancer therapy effectiveness.
In one embodiment, the method includes determining the expression levels of the proteins or the RNA transcripts for the biomarkers provided herein in Tables 5-13 in a sample from a patient with cancer. Biomarker expression in some instances may be normalized against the expression levels of all proteins or RNA transcripts in the sample, or against a reference set of proteins or RNA transcripts in the sample. The level of expression of the biomarkers is indicative of the prognosis for the subject or predictive of the effectiveness of a particular treatment.
The methods of the present disclosure can also be used to assist in selecting appropriate courses of treatment and to identify patients that would benefit; from a particular course of therapy. Thus, the expression of the particular biomarkers described herein provides insight into which cancer treatment regimens will be most effective for
the patient. This information can be used, to generate treatment plans for the patient to prolong survival and minimize side effects or cancer therapy related toxicity.
In some embodiments described herein, prognostic performance of the biomarkers and/or other clinical parameters was assessed utilizing a Cox Proportional Hazards Model Analysis, which is a regression method for survival data that provides an estimate of the hazard ratio and its confi dence interval The Cox mode! is a well-recognized statistical technique for exploring the relationship between the survival of a patient and particular variables. This statistical method permits estimation of the hazard (i.e., risk) of
individuals given their prognostic variables (e.g., expression level of particular biomarkers, as described herein). Survival data are commonly presented as Kaplan-Meier curves or plots. The "hazard ratio" is the risk of death at any given time point for patients displaying particular prognostic variables. See generally Spruance et a!., Antimicrob. Agents & Chemo. 48:2787-92, 2004. Methods for assessing statistical significance are well known in the art and include, for example, using a log-rank test. Cox proportional hazards model and Kaplan-Meier curves. In some aspects of the invention, a p-value of less than 0.05 constitutes statistical significance.
As used herein, the term "subject" and "patient" are used interchangeably mid refer to both human and non-human animals. The term "non-human animals" of the disclosure includes all vertebrates, e.g., mammals and non -mammals, such as nonhuman primates, sheep, dog, cat, horse, cow, chickens, amphibians, reptiles, and the like.
Preferably, the subject is a human patient. More preferably, the subject is a human patient diagnosed with cancer or undergoing, or about to undergo, a cancer treatment regimen.
The biomarkers of the present disclosure include proteins and genes encoding the proteins. The biomarkers analyzed are provided in Table 1 along with an indication of the commonly used abbreviations for each marker. Such biomarkers include DNA comprising the entire or partial sequence of the nucleic acid sequence encoding the biomarker, or the complement of such a sequence. The biomarker nucleic acids also include RNA comprising the entire or partial sequence of the nucleic acid sequences encoding the proteins of interest, A biomarker protein comprises the entire or partial amino acid sequence of any of the biomarker proteins or polypeptides.
Table 1. Angiogenic Factors analyzed
Abbreviations: A G-2, angiopoieim-2; bFGF, basic fibroblast growth factor; HGF, hepatocyte growth factor; IGFBP, insulin-like growth factor-binding protein; PDGF, platelet-derived growth factor: PEDF, pigment epithelium-derived factor; P1GF, placental growth factor; VEGF, vascular endothelial growth factor; sVEGFR, soluble vascular endothelial growth factor receptor; TGFp, transforming growth factor beta; TSP, thromhospondin; CRP, c-reactive protein; PAI-i, plasminogen activator inhibitor-! ; Greet; growth regulated oncogene-alpha; ICAM-1, intercellular adhesion molecule 1 ; EL, interleukin; MCP-I , macrophage chemoattractant protein- 1 ; SDF-1 stromal cell-derived factor-! ; VCAM-1, vascular cell adhesion molecule L
Fragments and variants of biomarker genes and proteins are also encompassed by the present invention. By "fragment" is intended a portion of the polynucleotide or a portion of the amino acid sequence and hence protein encoded thereby. Polynucleotides that are fragments of a biomarker nucleotide sequence generally comprise at least 10, 15, 20, 50, 75, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 800, 900, 1 ,000, 1,200, or 1 ,500 contiguous nucleotides, or up to the number of nucleotides present in a full-length biomarker polynucleotide disclosed herein. A fragment of a biomarker polynucleotide will generally encode at least 15, 25, 30, 50, 100, 150, 200, or 250 contiguous amino acids, or up to the total number of amino acids present in a full-length biomarker protein of the invention. "Variant" is intended to mean substantially similar sequences. Generally, variants of a particular biomarker of the invention will have at least about 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to that biomarker as determined by sequence alignment programs.
A "biomarker" is a gene or protein whose level of expression in a sample is altered compared to that of a normal or healthy sample or is indicative of a condition. The biomarkers disclosed herein are genes and proteins whose expression level correlates with cancer, particularly pancreatic cancer, prognosis or responsiveness of the cancer to a cancer therapy including a VEGF targeting agent.
In particular embodiments, the methods for predicting or prognosticating a cancer therapy in a subject includes collecting a patient body sample. The sample may or may not include cells. In particular, the methods described herein may be performed without requiring a tissue sample or biopsy and need not contain any cancer cells. In the
Examples, plasma was used. "Sample" is intended to include an sampling of cells, tissues, or bodily fluids In which expression of a biomarker can be detected. Examples of such samples include, but are not limited to, biopsies, smears, blood, lymph, urine, saliva, or any other bodily secretio or derivative thereof. Blood can include whole blood, plasma (citrate, EDTA, heparin), serum, or any derivative of blood. Samples may be obtained from a patien t by a variety of techniques available to those skilled in the art. Methods for collecting various samples are well known in the art.
Any methods available in the art for detectin expression of biomarkers are encompassed herein. The expression of a biomarker of the invention can be detected on a nucleic acid level (e.g., as an RNA transcript) or a protein level. By "detecting or determining expression" is intended determining the quantity or presence of a protein or its RNA transcript for at least one of the biomarkers of Table 1. Thus, "detecting expression" encompasses instances where a biomarker is determined not to be expressed, not to be detectably expressed,, expressed at a low level, expressed at a normal level, or overexpressed.
Methods suitable for detecting or determining the expression levels of biomarkers are known to those of skill in the art and include, but are not limited to, EL!SA, immunofluorescence, f ACS analysis, Western blot, magnetic Immunoassays, and both antibody-based micro arrays and non-antibody-based microarrays. In the p st, the gold standard for detection of growth factors and cytokines in blood was the use of E LIS As; however, multiplex technology offers an attractive alternative approach for cytokine and growth factor analysis. The advantages of multiplex technology compared to traditional
ELISA assays are conservation of patient sample, increased sensitivity, and significant savings in cost, time and labor.
Several multiplex platforms currently exist. The Luminex bead-based systems are the most established, being used to detect circulating cytokines and growth factors in both mice and humans. This method is based on the use of microparlicles that have been pre- coated with specific antibodies. These particles are then mixed with sample and the captured analytes are detected using specific secondary antibodies. This allows for up to 100 different analytes to be measured simultaneously in a single microplate well. The advantages of this flow cytometry-based method compared to traditional ELISA assays are in the conservation of patient samples as well as significant savings in terms of cost and labor. An alternative, plate-based system is produced by Meso Scale Discovery (MSD). This system utilizes its proprietary Multi-Array® and Multi-Spot® microplates with electrodes directly integrated into the plates. This enables the MSD system to have ultra-sensitive detection limits, high specificity, and low background signal. Another plate-based multiplex system i the Searchlight Plus CCD Imaging System produced by Aushon Biosystems. This novel multiplexing technology allows for the measurement of up to 16 different analytes simultaneously in a single microplate well. The assay design is similar to a sandwich ELISA where the capture antibodies are pre-spotted into individual wells of a 96-well plate. Samples or standards are added which bind to the specific capture antibodies and are detected using Aushotr s patented SuperSignal ELISA Femto Chemiluminescent Substrate.
in evaluating the multiple systems currently available, our laboratory has focused on the Searchlight system for several reasons. First, the assay portfolio is well aligned with many of the targets we are interested in measuring and second, the plate-based system has several operational advantages over the flow-based Luminex system, including lower maintenance costs, ease of use, and sim le-to-follow protocols. Notably any suitable assay may be used in the methods described herein. To date, we have used Searchlight technology to analyze 7 Phase I/O studies and one large Phase III studies (CALGB 80303). These multiplex analyses have been quality controlled to investigate ~ 40 analytes in various patient samples (i.e., serum, citrate plasma, EDTA plasma, and urine).
We have worked to optimize the design of -customized multiplex ELISA plates via extensive collaborations with Searchlight (recently acquired by Aushon Biosystems, Inc.). Considerable effort has been devoted in developing appropriately designed panels in order to evaluate over 40 regulators of tumor and normal angiogenesis (see Table 1 above). All plate designs were optimized for use in cancer patients in order to 1) limit cross-reactivity of the antibodies 2) optimize sensitivity and specificity and 3) maximize the linearity of the assay's dynamic range.
Methods for detecting expression of the biomarkers described herein are not limited to protein expression. Gene expression profiling including methods based on hybridization analysis of polynucleotides, methods based on sequencing of
polynucleotides, immunohistochemistry methods, and proteornics-based methods may also be used. The most commonly used methods known in the art for the quantification of mRNA expression in a sample include northern blotting and in situ hybridization (Parker and Barnes, Methods ol. Biol. 106:247-83, 1999), RNAse protection assays (Hod, Biotcchniqucs 13:852-54, 1992), PCR-based methods, such as reverse transcription PCR(RT-PCR) (Weis et al., TIG 8:263-64, 1992), and array-based methods (Schena et al, Science 270:467-70, 1995). Alternatively, antibodies may be employed that can recognize specific duplexes, including DNA duplexes, RNA duplexes, and DNA-RNA hybrid duplexes, or D A-protein duplexes. Representative methods for sequencing-based gene expression analysis include Serial Analysis of Gene Expression (SAGE) and gene expression analysis by massively parallel signature sequencing.
The terrn "probe" refers to any molecule that is capable of selectively binding to a specifically intended target biomolecule, for example, a nucleotide transcript or a protein encoded by or corresponding to a biomarker. Probes can be synthesized by one of skill in the art, or derived from appropriate biological preparations. Probes may be specifically designed to be labeled. Examples of molecules that can be util ized as probes incl ude, but are not limited to, RNA, DNA, proteins, antibodies, and organic molecules.
As used herein the term, "predicting responsiveness" refers to providing a probability based analysis of how a particular subject will respond to a cancer therapy. The prediction of responsi eness is not a guarantee or absolute, only a statistically probable indication of the responsiveness of the subject. The prediction of
responsiveness to a cancer therapy including a VEGF targeting agent may indicate that the subject is likely to be responsive to a cancer therapy including a VEGF targeting agent or alternatively may indicate that the subject is not likely to be responsive to a cancer therapy including a VEGF targeting agent. Alternatively, the prediction, may indicate that inclusion of a VEGF targeting agent in a cancer therapy regime may be counter-productive and lead to a worse result for the subject than if no therapy was used or a placebo was used. Responsiveness includes but is not limited to, any measure of a likelihood of clinical benefit. For example, clinical benefits include an increase in overall survival, an increase in progression free survival, an increase in time to progression, increased tumor response, decreased symptoms, or other quality of li e benefits.
A VEGF targeting agent includes any therapeutic agent targeting VEGF family members or any member of the VEGF receptor ciass of proteins. In particular, antibodies specific for VEGF, particularly VEGF-A, antibody-conjugated or other bloreagents capable of blocking VEGF mediated signaling, such as VEGF-R binding or competitive inhibitors, small molecules, aptamers, iRNAs, and other non-antibody-based therapeutic reagents, Anti-VEGF agents that are currently FDA approved include bevacizumab (Avastin™), sunitinib (Suten†™), sorafenib (Nexavar™), pazopanib (Voirient™), ranibizumab (Lucentis™), pegaptanib (Macugen™) and Axitinib (ln.iyte, M).
Bevacizumab is a monoclonal antibody against VEGF that is FDA approved for the treatment of metastatic colorectal cancer, lung cancer, , renal ceil cancer, and
glioblastoma. Sunitinib is a small molecule tyrosine kinase inhibitor that blocks VEGF, PDGF, and cKIT receptors; sunitinib is FDA approved for the treatment of renal cell carcinoma and Gl Stromal tumors (GIST). Sorafenib is a small molecule tyrosine kinase inhibitor that blocks VEGF, PDGF, and cKIT receptors as well as the oncogene Raf; sorafenib is FDA approved for the treatment of renal cell carcinoma and hepatocellular carcinoma. Pazopanib (Votrient™) is a small molecule tyrosine kinase inhibitor thai blocks VEGF, PDGF, and c !T receptors; pazopanib is FDA approved for the treatment of renal cell carcinoma. Ranibizumab (Lucentis™) is a Fab fragment antibody that binds VEGF; ranibizumab is FDA approved for the treatment neovascular (wet) age related macular degeneration (AMD). Pegaptanib (Macugen™) is a pegyiaied RNA aptamer that FDA approved- for the treatment neovascular (wet) age related macular degeneration
(AMD). Axitinib (IniyteTM) is a small molecule tyrosine kinase inhibitor capable of inhibiting VEGFRl, VEGFR2, VEGFR3, PDGFR and.cKIT thai is FDA approved for treatment of renal cell carcinoma. Multiple other VEGF and other angiogenesis inhibitors are in various stages of clinical development.
The VEGF targeting agents may be used in combination with other cancer therapeutics in a cancer therapy regimen. Combination therapy does not require that multiple cancer therapeutics be administered simultaneously, but only thai the subjects are treated with more than one therapeutic agent during a time span, such as one month, two months or more. For example, the VEGF targeting agent may be used in
combination with D'NA synthesis or DNA repair inhibitors such as nucleoside analogs. In the Examples, gemcitabine was used, but those of skill in the art will appreciate that a wide variety of cancer therapeutic agents are available arid that such agents are often used in combination such that a DNA synthesis inhibitor and other classes of anticancer agents, including but not limited to, other DNA damaging agents, anti-metabolites, hormonal therapies, and signal transduction inhibitors, is combined with a VEGF targeting agent in a cancer therapy. In the Examples, the patients were treated with gemcitabine ÷ placebo or gemcitabine -f bevacizumab.
The cancer ma be selected from any cancer in which a VEGF targeting agent is being considered for therapeutic purposes, in particular, the cancer may be a solid tumor. Cancers for which predictions may be made include but are not limited to pancreatic, colorectal, liver, esophageal, gastric, small bowel, cholangiocarcinoma, lung, head and neck, thyroid, melanoma, breast, renal, bladder, ovarian, uterine, prostate, lymphomas, !eukemias, neuroendocrine, glioblastoma or any other form of brain cancer.
hi the methods described herein the expression level of at least, one biomarker selected from ANG-2, SDF-l and VEGF-D in a sample from the subject is determined using any one of the detection methods described above. Then the level in the sample from the subject is compared to a reference level of the biomarker. The reference level may be determined empirically such as it was in the Examples, by comparison to the levels found in a set of samples from cancer patients treated with cancer therapies including or excluding a VEGF targeting agent with known clinical outcomes for the patients. Alternatively, the reference level may be a level of the biomarker found in
samples, such as plasma samples, which becomes a standard and can be used as a predictor for new samples. For example, the median cut-off levels reported in the Examples may now serve as reference levels for comparison. As noted in Table 3, the coefficients of variation were calculated for each biomarker and may be used to set reference levels. For example, a coefficient of variation of 20% would indicate that the median value could be altered by 20% and used as a reference level for the analysis.
In one embodiment, the expression level of ANG-2 and at least one of SDF-i, FGFb, OPN, F1GF and VCAM-1 are determined. In this embodiment, low levels of ANG-2 in combination with either low levels of SDF-1, FGFb or VCAM-i or high levels of OPN or HGF are predictive of lack of responsl veness of the cancer to treatment including a VEGF targeting agent. The prediction indicates unfavorabiiity of including a VEGF targeting agent in the cancer therapy when the expression level of Ang-2 is less than 305 pg/mL (310, 320, 330, 340, 350, 400, 450, or 500 pg/mL) and the expression level of SDF-1 is less than 1100 pg/mL (1200, 1300, 1400, 1500, 1600, 1700, or 2000 pg/mL), FGFb is less than 30 pg/mL (35., 40, 45, 50, 60, 70, 80, 90, or .100 pg/mL), VCAM-i is less than 1 ,700 ng/mL (1800, 1900, 2000, 2500, or 3000 ng mL), OPN is more than 73 ng/mL (70. 65, 6(3, 55, or 50 ng/mL) or HGF is more than 800 pg mL (810, 790, 780, 770, 760, or 750 pg mL). The lack of responsiveness to a VEGF targeting agent indicates a significant increase in clinical benefit to the subject when the subject is not treated with a VEGF targeting agent.
In another embodiment, the expression level of SDF-1 and OPN are determined, in this embodiment, high levels of SDF-1 and low levels of OPN are predictive of responsiveness to a VEGF targeting agent. The prediction favors responsiveness of the cancer to a cancer therapy including a VEGF targeting agent when the expression level of SDF-1 is more than 1 100 pg/mL (1050, 1000, 950, 900, 850, or 800 pg/mL) and OPN is less than 75 ng/mL (80, 85, 90, 95, or 100 ng mL). Responsiveness to a VEGF targeting agent indicates a significant increase in clinical benefit for subjects treated with a VEGF targeting agent.
in another embodiment, the expression level of SDF-I and at least one of PDGF- AA, 1GFBP-3, VEGF-R l or MCP-1 are determined. In this embodiment, low levels of SDF-1 in combination with either low levels of MCP-i or high levels of PDGF-AA,
1GFBP-3, or VEGF-RJ are predictive of lack of responsiveness of the cancer to ireatnieni including a VEGF targeting agent, The prediction indicates unfavorability of including a VEGF targeting agent in the cancer therapy when the expression level of SDF-1 is less than 1 100 ng/mL (1200, 1300, 1400, 1500, 1600, 1700, or 2000 pg/mL) and the expression level of MCP-1 is less than 525 pg/mL (550, 575. 600, 650, 700, or 750 pg/mL), PDGF-AA is more than 230 pg/mL (200, 175, 150, 125, 100, 75, or SO g/mL), IGFBP-3 is more than 700,000 ng/iriL (650,000, 600,000, 550,000, 500,000 or 450,000 ng/mL) or VEGF-R1 is more than 120 pg/mL. ( 100, 90, 80, 70 or 60 pg/mL). Lack of responsiveness to a VEGF targeting agent indicates a significant increase in clinical benefit for subjects not treated with a VEGF targeting agent.
in another embodiment, the expression level of HGF and at least one of MCP-1 or IGF-1 are determined, In this embodiment, high levels of HGF in combination with either low levels of MCP-1 or high levels of IGF-1 are predictive of lack of
responsiveness of the cancer to treatm ent including a VEGF targeting agent. The prediction indicates unfavorability of including a VEG F targeting agent in the cancer therapy when the expression level of HGF is more than 800 pg/raL (750, 700, 650, 600 or 550 pg/mL) and the expression level of MCP-1 is less than 525 pg/mL (550, 575, 600, 650, 700, or 750 pg/mL) o IGF-1 is more than 690 pg mL (675, 650, 625, 600, 550, 500 pg/mL). Lack of responsiveness to a VEGF targeting agent indicates a significant increase in clinical benefit for subjects not treated with a VEGF targeting agent.
In another embodiment, the expression level of VEGF-C and GROa are determined. In this embodiment, low levels of VEGF-C in combination with high levels of GROa are predictive of lack of responsiveness of the cancer to treatment including a VEGF targeting agent. The prediction indicates unfavorability of including a VEGF targeting agent in the cancer therapy when the expression level of VEGF-C is less than 575 pg/mL (600, 625, 650, 675, 700 or 725 pg/mL) and the expression level of GROa is more than 70 pg/mL (65, 60, 55, 50, or 45 pg/mL).
In another embodiment, low levels of VEGF-D are predictive of responsiveness to a VEGF targeting agent. In this embodiment, the prediction favors responsiveness to a cancer therapy including a VEGF tai-geting agent when the expression level of VEGF-D is less than 1050 pg/mL (1075, 1 100, 1 125, 1 150, 1 175, 1200, or 1250 pg/mL).
Responsiveness to a VEGF targeting agent indicates a significant increase in clinical benefit for subjects treated with a VEGF targeting agent.
I another embodiment, median, to high levels of VEGF-D are predictive of lack of responsiveness of the cancer to treatment including a VEGF targeting agent. The prediction is unfavorable for responsiveness to a cancer therapy including a VEGF targeting agent when the expression level of VEGF-D is more than 1100 pg/mL (1075 , 1050, 1025, 1000, 950, or 900 pg/mL). Lack of responsiveness to a VEGF targeting agent indicates a significant increase in clinical benefit for subjects not treated with a VEGF targeting agent.
The predictive methods described herein may be combined to provide increased significance of the results. For example, the levels of SDF-1, ANG-2 and OPN may all be determined in a sample from the subject. The levels may be compared to the reference levels and a prediction made. The prediction is favorable for responsiveness to a cancer therapy including a VEGF targeting agent if the SDF-1 levels are high, and the OPN levels are low. Alternatively, a sample with low SDF-1 and low ANG-2 will be predictive of lack of effectiveness of a VEGF targeting agent, in another embodiment, the test may further include VEGF-D, such that inclusion of a VEGF targeting agent is predictable to be favorable if the VEGF-D and OPN levels are low and the SDF-1 levels are high. Alternati vely, if the VEGF-D levels are not low, but instead are in the mid to high range as compared to the reference levels and the sample has low SDF-1 and low ANG-2, then a VEGF targeting agent will be predicted to not be effective as part of the cancer therapy.
Methods of developing a prognosis, in particular a survival or progression free survival prognosis, for a subject with pancreatic cancer is also provided herein. In one embodiment, the prognosis is independent of cancer therapeutic or cancer treatment regimen employed. In one embodiment, the subject may have localized, advanced or metastatic cancer. The method includes determining or detecting the expression level of biomarkers including IGFBP-1, PDGF-AA and at least one of IL-6 and CRP in a sample from the subject. The levels of the biomarkers present in the sample are then compared to reference levels as described above. Finally by comparison to the reference levels a prognosis for the subject can be determined.
In one embodiment, the expression levels of IGFBP-1 , PDGF-AA and IL-6 or CRP are measured and low levels are indicative of a better prognosis and high levels are indicative of poor prognosis, in one embodiment, the survival prognosis for the subject is less than 6 months when the expression level of IGFBP-1 is more than 13,000 pg/mL (12,750, 12,500, 12,000, 11,000, 10,000, 9,000 pg/mL), PDGF-AA is more than 225 pg/raL (200, 175, 150, 125, 100 or 75 pg/mL) and either IL-6 is more than 1.5 pg/mL (12, 10, 8, or 6 pg/mL) or CRP is more than 20,000 ng mL (39,000, 18,000, 17,000, 16,000 or 15,000 ng mL). In another embodiment, the survival prognosis for the subject is more than 6 months when the expression level of IGFBP-I is less than 13,500 pg/mL (13,250, 14,000, 15,000, 16,000, 17,000 pg/mL), PDGF-AA is less than 250 pg/mL (275, 300, 325, 350 or 400 pg/mL) and either IL-6 is less than 20 pg/mL (25, 30, 40, 50, 60, or 70 g mL) or CRP is less than 21 ,000 ng mL (22,000, 23,000, 24,000, 25,000 or 26,000 ng/mL).
In one embodiment, the expression level of IGFBP-i, PDGF-AA and CRP and the expression level of at least one of PAi-1 -total and PEDF are determined and low levels are indicative of a better prognosis and high levels are indicative of a poor prognosis. The survival prognosis for the subject is less than 6 months when the expression level of IGFBP-1 is more than 13,000 pg/mL (12,750, 12,500, 12,000, 1 1 ,000, 10,000, 9,000 pg/mL), PDGF-AA is more than 225 pg/mL (200, 175, 150, 125, 100 or 75 pg/mL), CRP is more than 20,000 ng/mL (19,000, 18,000, 17,000, 16,000 or 15,000 ng/mL), PAI-1 total is more than 2?,000pg/mL (26,000, 25,000, 24,000, 23,000 or 22,000 pg mL) and PEDF is more than 3,500 ng/mL (3250, 3000, 2750, 2500, or 2000 ng mL). The survival prognosis for the subject is more than 6 months when the expression level of IGFBP-1 is less than 13,500 pg/mL (13,250, 14,000, 15,000, 16,000, 17,000 pg mL), PDGF-AA is less than 250 pg mL (275, 300, 325, 350 or 400 pg/mL}, CRP is less than 21,000 ng/mL (22,000, 23,000, 24,000, 25,000 or 26,000 ng/mL), PAI-1 total is less than 28,000 pg/mL (29,000, 30,000, 31,000 or 32,000 pg/mL) and PEDF is less than 3,600 ng/mL (3750, 4000, 4250, 4500, or 5000 ng/mL). In one embodiment, the subject is being treated with emcitabine alone.
in another embodiment, the expression level of IGFBP-1, PDGF-AA and IL-6 and at least one of PDGF-BB and TSP-2 are determined. In this embodiment, low levels
of the biomarkers are indicative of a better prognosis and high levels are indicative of a poor prognosis. The survival prognosis for the subject is less than. 6 months when the expression level of IGFBP- 1 is more than 13,000 pg mL (12,750, 12,500, 12,000, 1 ,000, 10,000, 9,000 pg/mL), PDGF-AA is more than 225 pg/raL (200, 175, 150, 125, 100 or 75 pg mL), IL-6 is more than 15 pg/mL (12, 10, 8, or 6 pg/mL), PDGF-BB is more than 180 pg mL (175, 150, 125, 100, or 75 pg/mL) and TSP-2 is more than 20,000 pg mL (19,000, 18,000, 17,000, 16,000 or 15,000 pg/mL). The survival prognosis for the subject is more than. 6 months when the expression level of IGFBP-l is less than 13,500 pg/mL (13.250, 14,000, 15,000, 16,000, 17,000 pg/mL), PDGF-AA is less than 250 pg/mL (275, 300, 325, 350 or 400 pg/mL), IL-6 is less than 20 pg/mL (25, 30, 40, 50, 60, or 70 pg/raL), PDGF-BB is less than 190 pg/mL (200, 225, 250, 300, 350 or 400 pg raL) and TSP-2 is less than 21 ,000 pg mL (22,000, 23,000, 24,000, 25,000 or 26,000 pg/raL). In one embodiment, the subject is being treated with gemcitabine and a VEGF targeting agent.
In another embodiment, the expression level of at least one of ICAM-1, Ang2, IL- 8, TSP-2, VCAM-1 , ΡΑΪ-1 , and IGF-.! are determined. In this embodiment, low levels of ICAM-1, Ang2, IL-8, TSP-2, VCAM-1, or PAI-1 -active as compared to the reference level are indicative of a better prognosis and high levels of ICAM-1 , Ang2, IL-8, TSP-2, VCAM-1 , or PAI-1 -active as compared to the reference level are indicative of a poor prognosis, in this embodiment, high levels of IGF-1 as compared to the reference level is indicative of a better prognosis and low levels of IGF-1 as compared to the reference level is indicative of a poor prognosis.
In one embodiment, the survival prognosis for the subject is less than 6 months when the expression level of IGFBP-l is more than 13,000 pg mL (.12,750, 12,500, 12,000, 11 ,000, i 0,000, 9,000 pg/mL), or ICAM- 1 is more than 350 ng/mL (300, 275, 250, 225, or 200 ng/mL), or Ang2 is more than 300 pg/mL (275, 250, 225, 2005 175 or 150 pg/mL), or CRP is more than 20,000 ng/raL( 19,000, 18,000, 17,000, 16,000 or 15,000 ng/mL), or IL-8 is more than 49 pg/mL (45, 40, 35, 30 or 25 pg/mL), or IL-6 is more than 17 pg/mL(35, 12, 10, 8, or 6 pg/mL), or TSP-2 i more than 20,000 pg/mL (19,000, 18,000, 17,000, 16,000 or 15,000 pg mL), or VCAM-1 is more than 1,600 ng mL (1500, 1400, 1300, 1200 or 1100 ng/mL), or ΡΑΙ-Ϊ -active is more than 2200
pg/mL (2100, 2000, 1900, 1800 or 1700 pg/niL), or K3F-1 is less than 700 pg/raL (750, 800, 850, 900, or 1 00 pg/mL),
in one embodiment, survival prognosis for the subject is more than 6 months when the expression level of iGFBP-l is less than 13,500 pg/mL (13,250, 1.4,000, 15,000, i 6,000, 17,000 pg/raL), or ICAM- 1 is less than 360 ng/mL (375, 400, 425, 450, 475, or 500 ng/mL), or Ang2 is less than 305 pg/mL (310, 320, 330, 340, 350, 400, 450, or 500 pg/mL), or CRP is less than 21,000 ng/mL (22,000, 23,000, 24,000, 25,000 or 26,000 ng/mL), or IL--8 is less than 50 pg/raL (55, 60, 65, 70, 75, 80 or 85 pg/raL), or 1L-6 is less than 18 pg/tnL (20, 25, 30, 40, 50, 60, or 70 pg/mL), or TSP-2 i less than 21,000 pg/mL (22,000, 23,000, 24,000, 25,000 or 26,000 pg/mL), or VCAM- 1 is less than 1 ,700 ng mL (1800, 1 00, 2000, 2100 or 2200 ng/mL), or PAL 1 -active is less than 2300 pg/mL (2400, 2500, 2600, 2700, 2800 or 2900 pg/raL), or IGF-1 is more than 690 pg/raL (675, 650, 625, 600, 550, 500 or 450 pg/mL).
Methods of developing a treatment plan for a subject wit cancer are also provided herein, Treatment plans may be developed using the predictions of the responsiveness of the cancer to treatment with a cancer therapy including an antibody specific for VEGF-A obtained using the methods described herein to determine whether treatment of the subject with a cancer therapy including a VEGF targeting agent may e beneficial. The treatment plan will include a VEGF targeting agent if such a therapeutic is expected to be beneficial and the treatment plan will not include a VEGF targeting agent if it is not predicted to. be clinically beneficial to the subject as described above.
The following examples are meant only to be illustrative and are not meant as limitations on the scope of the invention, or of the appended claims, AH references cited herein are hereby incorporated by reference in their entireties,
EXAMPLES
Materials and Methods
Patients:
Eligibilit of patients evaluated in thi s correlative analysis was described previously (Kindier et al., 1 Clin Oncol 2010 28(22):3617-3622). Briefly, eligible patients had histologically- or cytologically-confirmed pancreatic adenocarcinoma not amenable
to curative surgery. Measurable disease was not required. Prior chemotherapy for metastatic disease was not permitted. Adjuvant chemotherapy was allowed if it did not contain gemcitabine or bevacizumab, if it was given more than 4 weeks before enrollment, and if the patient had subsequent disease progression. Prior radiation was allowed if it was completed at least 4 weeks prior to enrollment and there was disease outside the radiation port. Patients were required to be at least 18 years of age and have a life expectancy of at least 12 weeks. Written informed consent was obtained from all patients participating in this correlative analysis. Table 2 provides the demographic information for the patients.
Treatment:
Gemcitabine (1 ,000mg/m2) was administered intravenously over 30 rainut.es on days 1. 8, and 15 of a 28-day cycle. Bevacizumab ( 10 mg/kg) or placebo was given in travenously after gemcitabine on days 1 and 15 of each cycle, Bevacizumab or placebo
dose was Initiaiiy given over 90 minutes, and if no infusion reaction occurred, the second dose was given over 60 minutes, and subsequent doses were given over 30 minutes, IYeatment continued until progressive disease, unacceptable toxicities, or withdrawai of consent.
Sample Collection and Analysis:
Peripheral venous blood was collected from consenting patients into lavender (EDTA anticoagulant) vacutakiers for plasma isolation. The tubes were centrifuged at 2500 g for 15 minutes within 30 minutes of collection. Plasma was aliquoted into cryoviais, snap frozen, and samples shipped for centralized storage at the CALGB Pathology Coordinating Office. Before analysis, all patient samples were shipped to our laboratory (Duke/CALGB Molecular Reference Lab), thawed on ice, re-aliquoted based on specific assay requirements and stored at -80°C. Ail assays were performed in triplicate after 2 freeze-thaw cycles only and all analysis was conducted while blinded to clinical outcome.
Thirty-two biomarkers were analyzed using Searchlight platform (Aushon
Biosystems, inc., Billerica, MA) following manufacturer's protocol. Markers are listed in Table 1 above. Additional ELISA assays were conducted for !GF-i
(immunodiagnostic Systems, inc.; Seottsdale, Az) and TGFpRIO (R&D Systems. Inc.). Plasma samples were thawed on ice, centrifuged at 20,000 x g for 5 min to remove precipitate and loaded onto Searchlight plates with standard protein controls. Samples and standards were incubated at room temperature for 1 hour with shaking at 950 rpni (Lab-Line Titer Plate Shaker, Model 4625, Bamstead, Dubuque, IA). Plates were washed three times using a .plate washer (Biotek Instruments, inc.. Model ELx405, Winooski, VT), biotinylaied secondary antibody added, and incubated for 30 min. After washes, streptavidin-HRP was added, incubated for 30 min, washed again, and
SuperSignal substrate added. Images were taken within 10 min, followed by image analysis using Searchlight array analyst software.
Statistical Analysis:
Data from the 328 patients of metastatic pancreatic cancer treated with gemcitabine and bevacizumab demonstrate that the methods are highly reproducible. For 23 of 29 targets analyzed in EDTA using Searchlight Technology, coefficients of
variation were less than 20%. See Table 3. Both the ΤΟΡβΚΙΠ and IGF- 1 assays were performed using stand aid ELISA procedures and had coefficients of variation below 5%.
Asialyte Average Anaiyte Average
CV CV
i TGFp-RIII 2.60 17 CA.Vf- i 14.42
2 IGF- 1 3.73 18 IGFBP-1 14.46
3 P-seieeim 7.46 19 PEDF 14.68
4 IGFBP-3 7.94 20 ANG2 14.75
5 HGF 8.12 21 VEGF-R2 14.89
6 TSP-2 8.76 22 TGF 2 15.20
7 SDF- ! 9.44 23 PDGF-AA 17.69
8 VCAM-i 10.01 24 VEGF 17.90
9 ΡΑΠ total 10.07 25 VEGF-C 19.01
10 MCP-1 10.37 26 FGFb 20.09
1 1 V.EGF-D 10.69 27 PLGF 22.11
12 Π,-6 10.72 28 OPN 22.98
13 PAH active 1 1.30 29 GROa 24.26
14 PDGF-BB 12.21 30 IL-8 24.70
15 ΤΟΡβί ! 2.48 31 CRP 27.34
16 VEGF-R1 13,25
Table 3: Coefficients of Variation for Analyses tested
Patterns of expression were analyzed at baseline and were correlated with overall survival (OS) and progression free survival (PFS) using univariate Cox proportional hazard regression models and multivariate Cox models with leave-one-out cross validation. Spearman's rank correlation coefficients were calculated for all pairs of analytes. Unsupervised hierarchical clustering of analytes was also performed to produce dendrogram plots. Data indicate that several anaiyte clusters reflect known biological categories. This data is summarized in Figure 1 below.
Prior to statistical analysis, all data was initially reviewed for accuracy and quality. Any study samples that fell outside the linear portion of the standard cun'e were retestecl Samples that read below the limit of detection were retested at a lower dilution, if possible. Samples that read above the linear portion of the standard curve were serially diluted and retested to obtain accurate measurements. Any anaiyte that did not meet the aforementioned criteria resulted in the sample being re-evaluated. In the case of samples reading below the assay's limit of detection that cannot be re-assayed, we have developed
imputation methods to derive a number for such sampies, allowing for inclusion into our statistical approaches.
The primary endpoint of interest will be overall survival (OS) with correlation to the blood analytes; however, progression-free survival (PFS) was evaluated. Cox regression analysis was performed to assess the prognostic value of blood analytes for the clinical endpoints of interest. For each analyte, univariate Cox regression analysis was performed to assess the associations with OS and PFS ( ;::0,01 ). Cox regression models were performed for Gem+Piacebo and Gem-s-Bev separately. Raw, continuous analytes intensities for baseline measures were used. Summary statistics included the hazard ratios and associated confidence intervals. For each analyte, the inclusion of potential confounding factors was explored. These factors included; gender, extent of disease (locally advanced vs metastatic), age (continuous), and performance status (0, 1 , 2).
For PFS and OS, prognostic models were built with multivariate Cox regression analysis using the most informative analytes chosen from leave-one-out cross-validation for Gem+Placebo and Gem+Bev separately. At each leave-one-out iteration, the training samples were used to build a Cox regression model for predicting the survival of the testing samples. The predicted survival times were used to split the groups in half into high and low risk groups. Kaplan-Meier estimates of the hazard profiles for these two groups were produced.
Results
Basel in e Characteristics
Out of the 602 patients who accrued to the parent protocol, baseline EDTA plasma samples were available on 328 patients, 159 pis in the gemcitabine/placebo group and 169 in the gemeitabine/bevaeizumab group. The clinical characteristics and outcomes of these patients were similar to those on the parent study. Additionally, the two cohorts in this correlative study had similar characteristics across both groups, except for a minor imbalance in gender (Table 2 above).
Angiome Factor measurement and correlation
Thirty-one factors related to angiogenesis, inflammation, and coagulation were evaluated; standard ELISAs were used to evaluate IGF-1 and TGFpRIII while the
Searchlight system (Aushon BioSystems) was used to evaluate the remaining analytes.
Multiplex analyses denionsirated good sensitivity and coefficient's of variation (CVs) were generally in. the range of 10-30%, (Table 3), Only 2 analytes (PIGF and bFGF) had levels belo w the limits of quantification for greater than 10% of patients evaluated.
The median and range (high/low) for all analytes at baseline are provided in Table 4. Analyte values are presented in pg/niL or ng/mL, unless otherwise noted and data is provided for the study as a whole, as well as separated based on assigned cohort (trt 1~ bevacizumab-treated cohort; trt 2:::: placebo control cohort).
Table 4: Analyte concentrations Measured including Median and Range
IL-8(pg/mL) All : 328 49.2 0.59 2061.93 lL-8(pg/mL) 169 47.33 0.6 2061.93 iL-8(pgmL) 2 159 52.47 0.59 757.87
MCP-I{pg/i L) All 328 521.75 146.67 3445.5
MCP-l(pgmL) 1 [ 169 526.33 159 1653.67 j MCP-l(pg/mL) 2 159 517 146.67 3445.5
I OPN(ng/mL) All 328 74.06 1.55 1036.38
I OPN(ttg/mL) I 169 75.55 1.55 1036.38
1 OPN(ngmL) 2 159 69.32 1.56 292.35
PAll-act(pg/mL) All 1328 2295.2 3.8 31039.47
ΡΑΠ -act(pgmL) 1 169 2110.33 3.8 29658.27
PAIl-act(pgmL) 2 159 2517.73 121.07 31039.47
PAIl-tot(pgmL) All 328 27861.7 175.77 259313.3 j PAIl-iot(pg/mL) i 169 29570 175.77 259313.3 j PAl]-iot(pg/mL) 2 159 25866.7 5230 189496.7
1 P DGF- AA(pg/m L) All 32 239.2 0.47 5746.8 j
1 P DGF- AA (pg/ mL) 1 169 242.13 0.47 5746.8
PDGF-AA(pg/mL) 2 159 219,93 14.87 3544.67
PDGFbb(pgraL) All 328 185.4 0.27 2226.47
PDGFbb(pg/mL) 1 169 183.33 0.27 2226.47
PDGFbb(pgniL) 2 159 190.27 5.85 1386.13
PEDF(pg/mL) All 328 3549283 2636.55 7855183
PEDF(pg/roL) 1 169 3562750 2636.55 78551 3
PEDF(pg/mL) 2 159 3496300 225900 7364000 I
P-Selectin(ng/mL) All 328 53.59 3.63 624.47 j
P-SeIectin(ng/mL) 169 52.61 3.63 624.471
P~Selecin(ng/mL) 2 159 54.27 8.64 376.42
PlGF(pg/mL) All 328 5 0.13 363.13
PlGF(pg/mL) 1 169 4.8 0.13 363.13
PlGF(pg/raL) 2 159 5.4 0.27 186.67
SDF-j(pg/niL) ~~ΑΪΓ 328 1103.03 11.25 36383.73
SDF-l(pgmL) 1 169 1126.93 11.25 36383.73
SDF-l(pg/mL) 2 159 1021 88.6 5769
TGF i{pg/mL) All 326 36239.2 37.83 206971.7
TGF l(pg/mL) 1 168 37178.3 37.83 206971.7 !
TGF l(pg/mL) 2 158 32958.3 3818.33 1927651
TGFp2(pg;/ L) All 328 56.73 5.6 1286.87
TGFp.2(pg/mL) 1 169 56.73 8.73 440.93 j
TGF 2(pgmL) 2 159 56.73 5.6 1286.87
TGFf3~ 3{pg/mL) All 328 410.59 4.64 1011.55
TGF -R3(pg/mL) 1 I
1 i 169 431.15 4.64 1011.55 j
TGFp-R3 (pg/mL) 2 159 408.59 104.13 902.08
TSP-2(pg mL) All 328 20689.1 1528.5 451368.7
TSP-2(pg mL) 1 169 22708.7 1528.5 451368.7
TSP-2(pg/mL) 2 159 19353.3 5776 224395
VCAM-l(pg/mL) All 328 1614000 880 7971367
VCAM-l(pg/mL) 3 169 1621583 880 7199837
VCAM-l (pg mL) 2 159 1599333 225900 7973367
VEGF(pg mL) All 328 89.57 1.91 12678.2
VEGF(pg mL) 1 169 95.93 1.91 12678.2
VEGF(pg/mL) 2 159 82,47 1.91 3090.2
i V£GF-C(pg/raL) All 328 572.37 10.2 34037.87
VEGF-C(pg/mL) ! 169 588.53 10.2 34037.87
VEGF-C(pg mL) 2 159 554.3 44.19 4732.27
VEGF-D(pg mL) All 328 3558.1 70.31 25382.27
VEGF-D(pgZmL) 1 169 1574.07 70.31 13233.27
VEGF-D(pg/mL) 2 159 1553.73 359.93 25382.27
VEGF-Rl(pg/mL) All 328 122.97 8.2 43692.6 -
VEGF-Rl(pg mL) 1 169 130.33 8.2 16940.47
VEGF-Rl(pg mL) 2 359 1 12.93 32.53 43692.6
VEGF-R2(pg/mL) All 328 3790.5 34.17 l 3lj83 j
VEGF~R2(pg/mL) 1 169 3806.67 34.17 39032.83
VEGF~R2(pg mL) 2 159 3731.33 826.33 35116.17
To identify patterns of expression among anaiytes, Spearmen correlations were performed on all anaiytes and the following dendrogram was generated (Figure 1).
Interesting and biologically relevant associations were noted. These include associations within the VEGF PDGF families, as well as a broader association observed for multiple inflammatory markers. Strong coiTeiation coefficients (>0.70) were noted for only two pairs of anaiytes; TGFpl and PDGF-AA (0.76), CRP and IL-6 (0.72).
Prognostic Marker Identification
Univariate and multivariate Cox regression models were used to identify markers with statistically significant prognostic impact. Due to observed treatment-by-analyte interactions, both uni variate and multivariate prognostic analyses were conducted separately for the gemcitabine/placebo and the gemcitabme/bevacizumab groups. In the univariate analysis, IGFBP-1, lCAM-1 , Ang-2, CRP, IL-8, TSP-2, VCAM-i , PAll active, IGF- l , PAl l -total and P-selectin were significantly correlated with overall survival in the gemcitabine/placebo group (Table 5). In the univariate analysis, 3GFBP-3 ,
rCAM-1 , Ang-2, CRP, IL-8, TSP-2, VCAM-1 , ΡΑΪ1 active, and IGF-1 were significantly correlated with progression free survival in the gemcitabine/placebo group (Table 6). AH markers remained significant (p<0.05) after accounting for multiple parameter testing using bonferroni correction methodologies.
parameter testing using on erron correction met o s.
♦from Cox proportional hazard model using continuous anaiyte values.
< median > median < med vs > med p-vaiue* Median 95% CI Median j 95% CI Hazard T 95% CI
Survival Survival ratio
IGFBP-1 "o.ooooi 4.2 (3.5,5.6) j 2~5 ! (2.0,3.9) 1.4 ! (1.1 ,2.0)
ICAM.-l 6.9E-07 j 4.0 (2.8,5.5) ! 2.8 (2.0,4.2) 1.2 1 (0.85,1.62)
Ang2 0.000046 j 4.9 t (3.3,5.6) ! 2.2 ! (2.0,3.9) 1.7 ! (1 ,2,2.3)
CRP 0.00013 i 5.5 (4.1,5.8) ! 2.1 ΐ (1.8,2.8) 2.1 j ( 1.5.2.9)
IL-8 0.000017 ! 4.6 (3.7,5.5) I 2.3 j (2.0,3.6) 1.3 { (0.97, 1.8)
TSP-2 0.0043 ! 4.1 (2.7,5.5) ! 2.9 j (2.1,4.2) 1.6 Γα Π)
VCAM-1 ¾ 0.002 i 4.7 (2.7,5.8) j 2.8 (2.1,3.9) 1.7 j (ϊ.2,2.3)
ΡΑΪΙ-act 0.046 1 4.2 (2.9,5.5) 2.5 (2.0Λ0) 1.2 (0.88,1.67)
IGF-1 0.006 ""] 2.4 (2.0,3.9) 4.6 j (3.5,5.6) 0.69 (0.50,0.94)
Table 6. Univariate Progression-Free Survival P rognostk Markers at foase!isie
(EBTAs) for Gem+Ptacebo
Above is a list of analytes tha is prognostic univariately for overall survival using the Cox Proportional Hazard model. On the right hand side, it indicates the median survival
time and its 95% C.I for iess than median and greater than median level of the anaiytes. All anaiytes presented remain significant (p<0.05) after accounting for multiple parameter testing using bonferroni correction methods, *from Cox proportional hazard model using continuous analyte values.
TSP-2, CRP, IL-6, IGFBP-1 , Ang-2, ICAM-1, VCAM-1, and iGF-1 were significantly correlated with overall survival in the gemcitabine/bevacizumab group (Table 7). TSP-2, CRP, IL-6, IGFBP-1, Ang-2, ICAM-1, and VCAM-1 were significantly correlated with progression free survival in the gemcitabine bevacizumab group (Table 8), it should be noted that high consistency was observed across both cohorts. All of these factors were unfavorable prognostic markers, where higher levels were associated with a less favorable outcome. The only notable exception was IGF-1, where higher levels were associated with a .more favorable outcome. Additionally, all of these markers remained prognostic after correction for known clinical prognostic variables, including age, race, gender and performance status. Tables 9 and 10 are composite lists of anaiytes that are prognostic for overall survival and progression free survival irrespective of treatment condition, respectively.
*from Cox proportional hazard model using continuous analyte values.
Table 8. Univariate Progression-Free Survival Prognostic Markers at baseline (EBTAs) fo Gem+Bev
Above is a list of anaiytes that is prognostic univariate! y for progression free survival using the Cox Proportional Hazard model. On the right hand side, it indicates the median survival time and its 95% CI for less than median and greater than median level of the anaiytes. All anaiytes presented remain significant (p<0,Q5) after accounting for multiple parameter testing using bonferroni correction methods.
from Cox proportional hazard mode! using continuous analyte values
Above is a list of anaiytes that is prognostic imivariately for progression free survival using the Co Proportional Hazard model. On the right hand side, it indicates the median survival time and its 95% CI for less than median and greater than median level of the anaiytes. All anaiytes presented remain significant (p<0.Q5) after accounting for multiple parameter testing using bonferroni correction methods.
(EDTAs) for Gem-based treatment
Above is a list of analytes that is prognostic univariateiy for progression free survival using the Cox Proportional Hazard model. On the right hand side, it indicates the median survival time and its 95% CI for less than median and greater than median level of the analytes. All analytes presented remain significant (p<0.05) after accounting for multiple parameter testing using bonferroni correction methods.
*from Cox proportional hazard model using continuous analyte values
Multivariate prognostic models for OS (and PFS) were developed using a leave one out, cross-validation approach. Using this methodology, two 5-anaIyte models for risk were developed, one for the gemcilabine + placebo cohort, and another for gemcitabine + bevacizumab cohort (see Table 1 1), The gemcitabine + placebo model for OS consisted of IGFBP-1, CRP, PDGF-AA, ΡΑΠ -total, and PEDF. This model was associated with a hazard ratio of 2.0, with corresponding mediaii survivals of 3.3 and 7.3 months for the high and low-' risk groups, respectively. The gemcitabine ·÷■ bevacizumab mode! consisted of IGFBP-1 , IL-6, PDGF-AA, PDGF-BB, and TSP-2. This model was associated with a hazard ratio of 2.1, with corresponding median, survivals of 3.6 and 7.2 months for the high and low risk groups, respectively. Ail analytes appeared in greater than 95% of the models derived during analysis. Furthermore, analytes were observed to be consistent across the models. This data is represented in the Kaplan-Meier plots shown in Figure 2. For both the gemcitabine + placebo model (panel A) and the gemcitabine +
bevacizumab model (panel B) the high-risk groups are shown in solid lines, while the low risk groups are shown in dashed lines. In both cases, an approximate two-fold change in median survival was noted.
Table II. Baseline Multivariate EDTA Prognostic Models for Gem+PIacebo and
Gem+Bev (OS)
(cen) = censored Predictive Marker Identification
Predictive markers were identified using the Cox proportional hazards model. Analyte values were evaluated at both median and quartile outpoints. Three markers were identified as being predictive for bevacizumab benefit (or lack of benefit); VEGF- D, SDF1, and Ang-2. See Table 12. We observed thai low levels (below median) of both Ang-2 (p~0.G35) and SDF-l (p=0.027) predicted for greater benefit in the gemcitabine + placebo group (i.e., worse survival in the gemcitabine + bevacizumab group), interestingly, when VEGF-D was evaluated using quartile outpoints, low levels (below Ql, lowest 25% or less than 1092,35 pg/mL VEGF-D) predicted for benefit from bevacizumab (p:::0.033) while higher levels (above QL top 75% or more than 1092.35 pg/mL VEGF-D) of VEGF-D predicted for lack of benefit from bevacizumab (p-0.035). The data is shown graphically in Figure 3. Again, low levels of Ang-2 and SDF-l favored the placebo group, but a non-significant trend was noted for higher levels of these anaiytes predicting for benefit from bevacizumab. VEGF-D was see to be predictive across both sides of the Ql split.
em+ ev vs Gem+Placebo Next, the predictive impact of analyte pairs was evaluated. All pairs tested contained a factor that was found to be predictive upon univariate analysis. This bivariate analysis identified 12 pairs of analyies that were statistically significant predictors of benefit or lack of benefit from bevacizumab after correction for multiple testing (Table 13). The bivariate model which most strongly predicted for improved survival in the gemcitabine + bevacizumab group was the combination of SDF- lb (>median) and OPN (<median). See Figure 4. The model was associated with a hazard ratio of 0.55, with corresponding median survivals of 5.1 and 9.0 months for the gemcitabine -+· placebo group (shown in dashed lines) and gemcitabine ÷ bevacizumab (shown in solid lines), respectively. Alternatively, the bivariate model which most strongly predicted for worse survival in the gemcitabine + bevacizumab group was found to be SDF1 (< median) and Ang2 (< median). See Figure 5. This model was associated with a hazard ratio of 2.2, with corresponding median survivals of ,10.4 and 6.7 months for the gemcitabine + placebo group (shown in dashed lines) and gemcitabine + bevacizumab (shown in solid lines).
This multiplex angiome analysis of CALGB 80303 is one of the largest such analyses reported to date, and the first in metastatic pancreatic cancer, hi this large multicenter study, technical analyses were robust with good sensitivity and low variability, which were generally comparable to single kit ELISAs. Unsupervised hierarchical clustering identified potential patterns of analyte expression, with suggested grouping among VEGF/PDGF family members, ΤΟΡβ family members, and various inflammatory and coagulation factors. Such analyses, particularly across cancer types and in the settings of tumor response and progression, may provide novel insights into the co and counter regulation of these factors and their underlying biology.
Multiple prognostic markers were identified. This analysis is the largest and most comprehensive to date. These laboratory based prognostic markers were more powerful than traditional clinical factors and they remained highly statistically significant even
after adjustment for known clinical factors. Most of these markers are involved in tumor related angiogenesis, inflammation, and coagulation, confirming the clinical importance of the underlying pathophysiology of pancreatic cancer, indeed, ras mutations, which are present in approximately 90% of pancreatic adenocarcinomas, have been associated with the up-regulation of multiple factors related to inflammation and inflammatory angiogenesis and targeting these factors has been shown to inhibit the growth of xenograft and genetically modified mouse models of pancreatic cancer. Clinical trials with agents that inhibit these pathways are ongoing in various cancers, including pancreatic cancer; however, the value of targeting these factors in patients with pancreatic cancer is not yet known.
Multiple candidate markers of sensitivity and resistance to bevacizumab were also identified. The ability to assess for treatment interactions that can suggest such markers is a key advantage of randomized studies. The predictive importance of VEGF-D was highly statistically significant and low levels were associated with benefit from bevacizumab, and high levels were associated with resistance to bevacizumab, VEGF-D however was not found to he a general prognostic factor in this study. In. addition to VEGF-D, low levels of SDFl and Ang2 were identified on univariate analyses as potential predictors of resistance to bevacizumab. Bivariaie analyses confirmed the potential importance of these findings, and suggested that high levels of SDFl and low levels of OPN may predict for sensitivity to bevacizumab, Interestingly, Ang2 was noted to have significant general prognostic importance, while SDFl was not. Ang2 and SDFl are known to promote angiogenesis and thus the finding that low levels of these factors are associated with lack of benefit from bevacizumab may appear somewhat counter- intuitive. However, these factors are also associated with active angiogenesis and are known to he regulated by VEGF. Thus the current data are consistent with the known biology of both Ang2 and SDFl being VEGF context dependent.
in conclusion, multiple factors with strong prognostic impact for patients with pancreatic cancer were identified in the current analysis. In addition, VEGF-D was identified as a strong candidate for predicting sensitivity and resistance to bevacizumab in this population. Other candidates were also identified, highlighting the known complexity of tumor angiogenesis and pancreatic cancer.
Claims
1. A method of predicting responsiveness of a cancer in a .subject to a -cancer therapy including a VEGF targeting agent comprising; determining an expression level of at least one biomarker selected from Ang-2, SDF-1 and VEGF-D in a sample from the subject; comparing the expression level of the biomarker in the sample to a reference level of the biomarker; and predicting the responsiveness of the cancer to treatment with the cancer therapy including a VEGF targeting agent,
2. The method of claim 1 , wherein low levels of VEGF-D are predictive of
responsiveness to a VEGF targeting agent.
3. The method of claim 2, wherein the prediction favors responsiveness to a cancer therapy including a VEGF targeting agent when the expression level of VEGF-D is less than 1 100 pg/mL.
4» The method of claim 1 , wherein median to high levels of VEGF-D are predictive of lack of responsiveness of the cancer to treatment including a VEGF targeting agent.
5. The method of claim 4, wherein the prediction indicates lack of responsi eness to a a VEGF targeting agent when the expression level of VEGF-D is more than 1050 pg/mL.
6. The method of claim 1 , wherein the expression level of ANG-2 and at least one of SDF-1 , FGFb, OPN, HGF and VCAM-1 are determined.
7. The method of claim 6, wherein low levels of ANG-2 in combination with either low levels of SDF-1, FGFb or VCAM-1 or high levels of OPN or H GF are predictive of lack of responsiveness of the cancer to treatment including a VEGF targeting agent.
8. The method of claim 7, wherein tire prediction indicates lack of responsiveness to a VEGF targeting agent when the expression level of Ang-2 is less than 305 pg/mL and the expression level of SDF-1 is less than 1 100 pg/mL, FGFb is less than 30 pg/m L, VCAM-1 is less than 1 ,700 ng mL, OPN is more than 73 ng/mL or HGF is more than 800 pg/mL.
9. The method of claim 1 , wherein the expression level of SDF-1 and at least one of OPN, PDGF-AA, IGFBP-3, VEGF-R1 or MCP-1 are determined.
10, The method of claim 9, wherein high levels of SDF-1 and low levels of OPN are predictive of responsiveness to a VEGF targeting agent,
11. The method of claim 10, wherein the prediction favors responsiveness of the cancer to a cancer therapy including a VEGF targeting agent when the expression level of SDF-1 is more than .1 100 pg/niL and OPN is less than 75 ng/mL.
12. The method of any one of claims 2, 3, 10 or 3 1 , wherein responsiveness to a VEGF targeting agent indicates a significant increase in clinical benefit for subjects treated ith a VEGF targeting agent.
13. The method of claim 9, wherein low levels of SDF-1 in combination with either low levels of MCP-1 or high levels of PDGF-AA, IGFBP-3, or VEGF-R 1 are predictive of lack of responsiveness of the cancer to treatment including a VEGF targeting agent.
14, The method of claim .13, wherein the prediction indicates lack of responsi veness to a VEGF targeting agen when the expression level, of SDF-1 is less than 1 100 ng/mL and the expression level of MCP-1 is less than 525 pg/mL, PDGF-AA is more than 230 pg/mL, iGFBP-3 is more than 700,000 ng/mL, or VEGF-R1 is more than 120 pg/mL.
15. The method of claim 1 , wherein the expression level of HGF and at least one of
MCP-1 or IGF-l are determined.
16, The method of claim 15, wherein high levels of HGF in combination with either low levels of MCP-1 or high levels of IGF-l are predictive of lack of
responsiveness of the cancer to treatment including a VEGF targeting agent,
17. The method of claim 16, wherein the prediction indicates lack of responsiveness to a VEGF targeting agent when the expression level of HGF is more than 800 pg/mL and the expression level of MCP-2 is less than 525 pg/mL or IGF~1 is more than 690 pg/mL.
18. The method of claim 1, wherein the expression level of VEGF-C and GROa are determined.
1 . The method of claim 18. wherein low levels of VEGF-C in combination with high levels of GROa are predictive of lack of responsiveness of the cancer to treatment including a VEGF targeting agent.
20. The method of claim 19, wherein the prediction indicates unfevorability of
including a VEGF targeting agent in the cancer therapy when the expression level of VEGF-C is less than 575 pg/mL and the expression level of GROa is more than 70 pg.'mL.
21. The method of any one of claims 4, 5, 7, 8. 13, 14, 16, 17, 1 or 20, wherein lack of responsiveness to a VEGF targeting agent indicates a significant increase in clinical benefit for subjects not treated with a VEGF targeting agent.
22. The method of claim 1 , wherein the expression level of Ang-2, SDF-1 and VEGF- D are determined.
23. The method of any one of claims 1-22, wherein the reference level is determined by analysis of a set of samples from cancer patients treated with cancer therapies including or excluding a VEGF targeting agent with known outcomes.
24. The method of any one of claims 1 -23, wherein the VEGF targeting agent is
bevaeizumab.
25. The method of any one of claims 1-24, wherein the cancer therapy includes a nucleotide analog or other inhibitor of DNA synthesis and repair,
26. The method of claim 25, wherein the inhibitor is gemcitabine.
27. The method of any one of claims 1-26, wherein the cancer is selected from the group consisting of pancreatic, colorectal, liver, esophageal, gastric, small bowel, cholangiocarcinoma, lung, head and neck, thyroid., melanoma, breast, renal, bladder, ovarian, uterine, prostate, lymphomas, !eukemias, neuroendocrine, glioblastoma or any other form of brain cancer.
28. A method of developing a prognosis for a subject diagnosed with pancreatic
cancer comprising: determining an expression level of IGFBP-l, PDGF-AA and at least one of IL-6 and CRP in a sample from the subject; comparing the expression levels of IGFBP-1 , PDGF-AA and at least one of IL-6 and CRP in the sample to reference levels; and determining a survival prognosis for the subject.
29. The method of claim 28, wherein the expression levels of IGFBP-i, PDGF-AA and IL-6 or CRP axe m easured and wherein low levels are indicative of a better prognosis and high levels are indicative of poor prognosis.
30. The method of claim 29. wherein the survival prognosis for the subject is les than 6 months when the expression level of IGFBP-l is more than 13,000 pg/mL,
PDGF-AA is more than 225 pg/rnL and either IL-6 is more than 15 pg/mL or CRP is more than 20,000 ng/ml,
31. The method of claim 29, wherein the survival prognosis for the subject is more than 6 months when the expression level of IGFBP-l is less than 13,500 pg/mL, PDGF-AA is less than 250 pg/mL and either .IL-6 is less than 20 pg/mL or CRP is less than 2.1 ,000 ng/mL,
32. The method of any one of claims 28-3 ! , wherein the expression level of CRP is determined and further comprising determining the expression level of at least one of PAI-1 -total and PEDF, wherein low levels of either are indicative of a better prognosis and high levels of either are indicative of a poor prognosis.
33. The method of claim 32, wherein the survival prognosis for the subject is less than 6 months when the expression level of IGFBP-l is more than 13,000 pg/mL, PDGF-AA is more than 225 pg/mL, CRP is more than 20,000 ng/mL, PA total is more than 27,000pg/mL and PEDF is more than 3,500 ng/mL,
34. The method of claim 32, wherein the survival prognosis for the subject is more than. 6 months when the expression level of IGFBP-i is less than 13,500 pg/mL, PDGF-AA is less than 250 pg/mL, CRP is less than 21,000 ng mL, PAI- 1 total is less than 28.000 pg/mL and PEDF is less than 3,600 ng/mL.
35. The method of any one of claims 32-34, wherein the subject is being treated with gemcitabine.
36, The method of any one of claims 28-31 , further comprising determining the
expression level of at least one of PDGF-BB and TSP-2, wherein low levels of either are indicative of a better prognosis and high levels of either are indicative of a poor prognosi s,
37. The method of claim 36, wherein the survival prognosis for the subject is less than 6 months when the expression level of IGFBP-l is more than 13,000 pg mL,
PDGF-AA is more than 225 pg/mL, IL-6 is more than 15pg mL, PDGF-BB is more than 180 pg/mL and TSP-2 is more than 20,000 pg/mL.
38. The method of claim 36, wherein the survival prognosis for the subject is more than 6 months when the expression level of IGFBP-l is less than 13,500 pg/mL, PDGF-AA is less than 250 pg/mL, IL-6 is less than 20 pg/mL, PDGF-BB is less than 1 0 pg/mL and TSP-2 is less than 21,000 pg/mL.
39. The method of any one of claims 36-38, wherein the subject is being treated with gemcitabine and a VEGF targeting agent,
40. The method of any one of claims 28-39, wherein a better prognosis indicates the subject has a median survival of more than 6 months from the date on which the sample was obtained.
41. The method of any one of claims 28-39, wherein a poor prognosis indicates the subject has a median survival of less than 6 months from the date on which the sample was obtained.
42. The method of any one of claims 28-41 , further comprising determining the
expression level of at least one of ICAM-l , Ang2, IL-8, TSP-2, VCAM-1, PAI-1, and IGF-1.
43. The method of claim 42, wherein low levels of ICAM-l, Ang2, IL-8, TSP-2, VCAM-1 , or PAI-1 -active as compared to the reference level are indicative of a b etter progno sis .
44. The method of claim 42, wherein high levels of ICAM-l , Ang2, IL-8, TSP-2, VCAM-1, or ΡΑΪ-1 -active as compared to the reference level are indicative of a poor prognosis.
45. The method of claim 42, wherein high levels of IGF- 1 as compared to the
reference level is indicative of a better prognosis.
46. The method of claim 42, wherein low levels of IGF- 1 as compared to the
reference level is indicative of a poor prognosis.
47. The method of any one of claims 28-46, wherein the reference level is determined by analysis of a set of samples from pancreatic cancer patients with known outcomes.
48 , The method of any one of claims 28-47, wherein the survival prognosis for the subject is less than 6 months when the expression, level of IGFBP-1 is more than 13,000 pg/mL, or ICAM-1 is more than 350 ng/mL, or Ang2 is more than 300 pg/mL, or CRP is more than 20,000 ng/mL, or IL-8 is more than 49 pg raL, or IL-6 is more than 17 pg mL, or TSP-2 is more than 20,000 pg/mL, or VCAM-1 is more than 1,600 ng mL, or PAI-i -active is more than 2200 pg/mL, or IGF-1 is less than 700 pg/mL.
49, The method of any one of claims 28-47, wherein the survival prognosis for the subject is more than 6 months when the expression level of IGFBP-1 is less than 13,500 pg/mL, or ICAM- 1 is less than 360 ng/mL, or Ang2 is less than 310 pg mL. or CRP is less than 21,000 ng/mL, or IL-8 is less than 50 pg/mL, or IL-6 is less than 18 pg mL, or TSP-2 is less than 21,000 pg/mL, or VCAM-1 is less than 1,700 ng/mL, or ΡΑΪ-l -active is less than 2300 pg/mL, or IGF-1 is more than 690 pg/mL.
50. The method of any one of the preceding claims, wherein the sample is blood, plasma, serum, or urine.
51. The method of any one of the preceding claims, wherein the expression level of the biomarker determined is the protein or RNA expression level.
52. The method of claim 51 , wherein the protein expression level is determined by a method selected from ELISA, immunofluorescence, FACS analysis, Western blot. magnetic immunoassays, and antibody-based microarrays.
53. The method of claim 51, wherein the RNA expression level is determined by a method selected from Northern blot. rtPCR, and quantitative or real-time rtPCR.
54. A method of developing a treatment plan for a subject with cancer comprising using the prediction of the responsiveness of the cancer to treatment with a cancer therapy including an antibody specific for VEGF-A obtained from any one of claims 1-27 to determine whether treatment of the subject with a cancer therapy including a VEGF targeting agent may be beneficial, wherein the treatment plan will Include a VEGF targeting agent if such a therapeutic is expected to be beneficial.
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12779776.9A EP2704745B1 (en) | 2011-05-05 | 2012-05-07 | Methods of developing a prognosis for pancreatic cancer and predicting responsiveness to cancer therapeutics |
US14/115,825 US9255927B2 (en) | 2011-05-05 | 2012-05-07 | Methods of developing a prognosis for pancreatic cancer and predicting responsiveness to cancer therapeutics |
US15/001,419 US9869677B2 (en) | 2011-05-05 | 2016-01-20 | Methods of developing a prognosis for pancreatic cancer and predicting responsiveness to cancer therapeutics |
US15/868,541 US10613091B2 (en) | 2011-05-05 | 2018-01-11 | Methods of developing a prognosis for pancreatic cancer and predicting responsiveness to cancer therapeutics |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161482757P | 2011-05-05 | 2011-05-05 | |
US61/482,757 | 2011-05-05 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/115,825 A-371-Of-International US9255927B2 (en) | 2011-05-05 | 2012-05-07 | Methods of developing a prognosis for pancreatic cancer and predicting responsiveness to cancer therapeutics |
US15/001,419 Division US9869677B2 (en) | 2011-05-05 | 2016-01-20 | Methods of developing a prognosis for pancreatic cancer and predicting responsiveness to cancer therapeutics |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2012151574A1 true WO2012151574A1 (en) | 2012-11-08 |
Family
ID=47108077
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2012/036779 WO2012151574A1 (en) | 2011-05-05 | 2012-05-07 | Methods of developing a prognosis for pancreatic cancer and predicting responsiveness to cancer therapeutics |
Country Status (3)
Country | Link |
---|---|
US (3) | US9255927B2 (en) |
EP (1) | EP2704745B1 (en) |
WO (1) | WO2012151574A1 (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2548321C1 (en) * | 2014-06-10 | 2015-04-20 | Государственное бюджетное образовательное учреждение дополнительного профессионального образования "Новокузнецкий государственный институт усовершенствования врачей" Министерства здравоохранения Российской Федерации | Method of assessing clinical course of acute biliary pancreatitis |
WO2017201166A1 (en) * | 2016-05-17 | 2017-11-23 | Duke University | Methods of predicting responsiveness of a cancer to a vegf targeting agent and methods of prognosing and treating cancer |
US9869542B2 (en) | 2014-04-21 | 2018-01-16 | Axsun Technologies, Inc. | System and method for resampling optical coherence tomography signals in segments |
CN108496084A (en) * | 2016-01-25 | 2018-09-04 | 赛诺菲 | The method that the doubtful patient with cancer of horizontal forecast by measuring blood plasma biomarker uses the result of the treatment of VEGF Trap |
WO2018225062A1 (en) * | 2017-06-04 | 2018-12-13 | Rappaport Family Institute For Research In The Medical Sciences | Method of predicting personalized response to cancer therapy and kit therefor |
US11908560B2 (en) | 2021-08-11 | 2024-02-20 | OncoHost Ltd. | Cancer process evaluation |
US12016900B2 (en) | 2017-06-04 | 2024-06-25 | Rappaport Family Institute For Research In The Medical Sciences | Method of treating cancer with an immune checkpoint inhibitor in combination with another therapeutic agent |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012151574A1 (en) | 2011-05-05 | 2012-11-08 | Duke University | Methods of developing a prognosis for pancreatic cancer and predicting responsiveness to cancer therapeutics |
WO2016126682A1 (en) * | 2015-02-03 | 2016-08-11 | Momenta Pharmaceuticals, Inc. | Methods of controlling therapeutic regimens |
WO2017190074A1 (en) * | 2016-04-28 | 2017-11-02 | The University Of Chicago | Lymphangiogenesis for therapeutic immunomodulation |
EP3710466A2 (en) | 2017-11-13 | 2020-09-23 | The University of Chicago | Methods and compositions for the treatment of wounds |
CN109234365A (en) * | 2018-11-13 | 2019-01-18 | 武汉科技大学 | A method of detection miR5100, CXCL-12 and IL-8 relative expression quantity |
JPWO2023276869A1 (en) * | 2021-06-28 | 2023-01-05 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060223770A1 (en) * | 2004-03-12 | 2006-10-05 | Fougerolles Antonin D | IRNA agents targeting VEGF |
WO2009155504A2 (en) * | 2008-06-20 | 2009-12-23 | The Children's Medical Center Corporation | Methods for the modulation of angiogenesis |
US20100055099A1 (en) * | 2008-08-29 | 2010-03-04 | Ellen Filvaroff | Diagnostics and Treatments for VEGF-Independent Tumors |
US20110076271A1 (en) * | 2009-07-13 | 2011-03-31 | Genentech, Inc. | Diagnostic methods and compositions for treatment of cancer |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001085796A2 (en) | 2000-05-12 | 2001-11-15 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Use of inhibitors of placental growth factor for the treatment of pathological angiogenesis, pathological arteriogenesis, inflammation, tumour formation and/or vascular leakage |
US20080248033A1 (en) | 2006-12-19 | 2008-10-09 | Genentech, Inc. | VEGF-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors |
WO2010048304A2 (en) * | 2008-10-21 | 2010-04-29 | Bayer Healthcare Llc | Identification of signature genes associated with hepatocellular carcinoma |
EP2293071A1 (en) * | 2009-09-07 | 2011-03-09 | Universität Zu Köln | Biomarker for colorectal cancer |
WO2012151574A1 (en) | 2011-05-05 | 2012-11-08 | Duke University | Methods of developing a prognosis for pancreatic cancer and predicting responsiveness to cancer therapeutics |
-
2012
- 2012-05-07 WO PCT/US2012/036779 patent/WO2012151574A1/en active Application Filing
- 2012-05-07 US US14/115,825 patent/US9255927B2/en active Active
- 2012-05-07 EP EP12779776.9A patent/EP2704745B1/en not_active Not-in-force
-
2016
- 2016-01-20 US US15/001,419 patent/US9869677B2/en active Active
-
2018
- 2018-01-11 US US15/868,541 patent/US10613091B2/en not_active Expired - Fee Related
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060223770A1 (en) * | 2004-03-12 | 2006-10-05 | Fougerolles Antonin D | IRNA agents targeting VEGF |
WO2009155504A2 (en) * | 2008-06-20 | 2009-12-23 | The Children's Medical Center Corporation | Methods for the modulation of angiogenesis |
US20100055099A1 (en) * | 2008-08-29 | 2010-03-04 | Ellen Filvaroff | Diagnostics and Treatments for VEGF-Independent Tumors |
US20110076271A1 (en) * | 2009-07-13 | 2011-03-31 | Genentech, Inc. | Diagnostic methods and compositions for treatment of cancer |
Non-Patent Citations (9)
Title |
---|
GEORGE ET AL.: "VEGF-A, VEGF-C, VEGF-D in Colorectal Cancer Progresssion.", NEOPLASIA, vol. 3, no. 5, 17 September 2001 (2001-09-17), pages 420 - 427, XP002550937 * |
HOD, BIOTECHNIQUES, vol. 13, 1992, pages 852 - 54 |
KINDLER ET AL., J CLIN ONCOL, vol. 28, no. 22, 2010, pages 3617 - 3622 |
MARTIN ET AL.: "High-Sensitivity Array Analysis of Gene Expression for the Early Detection of Disseminated Breast Tumor Cells in Peripheral Blood.", PNAS, vol. 98, no. 5, 27 February 2001 (2001-02-27), pages 2646 - 2651, XP002188522 * |
PARKER; BARNES, METHODS MOL. BIOL., vol. 106, 1999, pages 247 - 83 |
SCHENA ET AL., SCIENCE, vol. 270, 1995, pages 467 - 70 |
See also references of EP2704745A4 |
SPRUANCE ET AL., ANTIMICROB. AGENTS & CHEMO., vol. 48, 2004, pages 2787 - 92 |
WEIS ET AL., TIG, vol. 8, 1992, pages 263 - 64 |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9869542B2 (en) | 2014-04-21 | 2018-01-16 | Axsun Technologies, Inc. | System and method for resampling optical coherence tomography signals in segments |
RU2548321C1 (en) * | 2014-06-10 | 2015-04-20 | Государственное бюджетное образовательное учреждение дополнительного профессионального образования "Новокузнецкий государственный институт усовершенствования врачей" Министерства здравоохранения Российской Федерации | Method of assessing clinical course of acute biliary pancreatitis |
CN108496084A (en) * | 2016-01-25 | 2018-09-04 | 赛诺菲 | The method that the doubtful patient with cancer of horizontal forecast by measuring blood plasma biomarker uses the result of the treatment of VEGF Trap |
WO2017201166A1 (en) * | 2016-05-17 | 2017-11-23 | Duke University | Methods of predicting responsiveness of a cancer to a vegf targeting agent and methods of prognosing and treating cancer |
US11499973B2 (en) | 2016-05-17 | 2022-11-15 | Duke University | Methods of predicting responsiveness of a cancer to a VEGF targeting agent and methods of prognosing and treating cancer |
WO2018225062A1 (en) * | 2017-06-04 | 2018-12-13 | Rappaport Family Institute For Research In The Medical Sciences | Method of predicting personalized response to cancer therapy and kit therefor |
JP2020522707A (en) * | 2017-06-04 | 2020-07-30 | ラパポート・ファミリー・インスティテュート・フォー・リサーチ・イン・ザ・メディカル・サイエンシーズRappaport Family Institute for Research in the Medical Sciences | Method and kit for predicting individualized response to cancer treatment |
EP3635403A4 (en) * | 2017-06-04 | 2021-04-21 | Rappaport Family Institute for Research in the Medical Sciences | Method of predicting personalized response to cancer therapy and kit therefor |
JP7348074B2 (en) | 2017-06-04 | 2023-09-20 | ラパポート・ファミリー・インスティテュート・フォー・リサーチ・イン・ザ・メディカル・サイエンシーズ | Method and kit for predicting individualized response to cancer therapy |
US11977075B2 (en) | 2017-06-04 | 2024-05-07 | Rappaport Family Institute For Research In The Medical Sciences | Method of predicting personalized response to cancer treatment with immune checkpoint inhibitors, method of treating cancer, and kit therefor |
US12016900B2 (en) | 2017-06-04 | 2024-06-25 | Rappaport Family Institute For Research In The Medical Sciences | Method of treating cancer with an immune checkpoint inhibitor in combination with another therapeutic agent |
US11908560B2 (en) | 2021-08-11 | 2024-02-20 | OncoHost Ltd. | Cancer process evaluation |
Also Published As
Publication number | Publication date |
---|---|
US20160146822A1 (en) | 2016-05-26 |
EP2704745A1 (en) | 2014-03-12 |
EP2704745B1 (en) | 2016-12-14 |
EP2704745A4 (en) | 2014-10-15 |
US20140127193A1 (en) | 2014-05-08 |
US9869677B2 (en) | 2018-01-16 |
US9255927B2 (en) | 2016-02-09 |
US20180156804A1 (en) | 2018-06-07 |
US10613091B2 (en) | 2020-04-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10613091B2 (en) | Methods of developing a prognosis for pancreatic cancer and predicting responsiveness to cancer therapeutics | |
US8580520B2 (en) | YKL-40 as a marker for gastrointestinal cancers | |
US20150197819A1 (en) | Biomarkers and methods for determining efficacy of anti-egfr antibodies in cancer therapy | |
JP6055764B2 (en) | Plasma biomarkers for bevacizumab combination therapy for the treatment of breast cancer | |
JP5963005B2 (en) | Plasma biomarkers for bevacizumab combination therapy for the treatment of pancreatic cancer | |
JP6622722B2 (en) | Pulmonary hypertension biomarker | |
Chen et al. | VEGF− 460T→ C polymorphism and its association with VEGF expression and outcome to FOLFOX-4 treatment in patients with colorectal carcinoma | |
KR20170129118A (en) | Biomarkers for pancreatic cancer | |
US20160024585A1 (en) | Methods of predicting responsiveness of a cancer to an agent and methods of determining a prognosis for a cancer patient | |
WO2019010429A1 (en) | Methods for diagnosing pancreatic cancer | |
EP3080299B1 (en) | Biomarkers of rapid progression in advanced non-small cell lung cancer | |
WO2021116057A1 (en) | Biomarker panel for diagnosing colorectal cancer | |
EP2309271A1 (en) | Methods for predicting the responsiveness of a patient affected with a tumor to a treatment with a tyrosine kinase inhibitor | |
US11499973B2 (en) | Methods of predicting responsiveness of a cancer to a VEGF targeting agent and methods of prognosing and treating cancer | |
EP3640643B1 (en) | Method for predicting the outcome of a treatment with aflibercept of a patient suspected to suffer from a cancer by measuring the level of a plasma biomarker | |
JP6899848B2 (en) | Biomarkers, test methods, and test kits for predicting the therapeutic effect of anti-VEGFR-2 antibody drugs | |
Basuroy et al. | Personalized medicine for gastroenteropancreatic neuroendocrine tumors: a distant dream? | |
Adachi et al. | Tumor Marker Publication | |
US20110269139A1 (en) | Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators | |
US9823256B2 (en) | CXCR1 as a predictor of response to treatment with epidermal growth factor receptor therapeutic | |
US20220082565A1 (en) | The fgf19-cholestyramine (f-cme) test as a two-stage method for routine cancer screening | |
KR20230086458A (en) | Novel Biomarker for Predicting Therapeutic Response and Prognosis of Metastatic Breast Cancer To Chemotherapeutic Agents and Uses Thereof | |
KR20230084061A (en) | Biomarker for predicting prognosis post-neoadjuvant chemotherapy of breast cancer patient and use thereof | |
KR20180073304A (en) | Biomarker for predicting asthma and method of prediction for asthma using the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12779776 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REEP | Request for entry into the european phase |
Ref document number: 2012779776 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012779776 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14115825 Country of ref document: US |